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Abstract 
ABSTRACT 
Background: Oral submucous fibrosis (OSF) is a chronic progressive premalignant 
condition of the oral cavity associated with significant morbidity. Wide range of 
investigations have been carried out in this condition to identify the causation and 
pathogenesis. Biochemical investigations have been the earliest form of intervention to 
localize the parameters that predispose to the development of the condition and 
prognosticate on its malignant transformation potential. Only few studies have been done 
to estimate homocysteine level before treatment in oral submucous fibrosis. Hence the 
present study was conducted to evaluate the serum homocysteine level in oral submucous 
fibrosis in various stages before and after medical intervention and to compare and assess 
the serum homocysteine level as a prognostic marker in oral submucous fibrosis. 
Aim: To evaluate the serum homocysteine level as prognostic marker in oral submucous 
fibrosis. 
Objective: To estimate serum homocysteine in patients with oral submucous fibrosis in 
various stages before and after treatment. To compare the serum homocysteine level 
before and after treatment and assess the value of serum homocysteine level as a 
prognostic marker. 
Methods: A total of 37 study participants comprising of 30 OSF patients and 7 healthy 
controls were included in the study. OSF patients were graded clinically into 4 grades. All 
the participants were subjected to homocysteine evaluation. OSF patients were treated 
with intralesional steroid and supplemental medication for 6 weeks and evaluated for 
improvement in burning sensation, mouth opening and post treatment Homocysteine. All 
the values were statistically analysed and the results were drawn. 
 
Abstract 
Results: The average age of study participants was 31.59±7.588 years. Majority of OSF 
patients were males. The mean serum homocysteine level in male and female are 
19.82µmol/L and 8.86µmol/L. The mean serum homocysteine level in control group 
(8.40±1.74µmol/L) and OSF group (20.67±11.26µmol/L) showed statistically significant 
difference. With progression of disease from Grade I (10.69±2.26µmol/L) to Grade IV 
(35.17±13.90µmol/L), a statistically significant increase in mean serum homocysteine 
level was observed. The post treatment mean serum homocysteine levels in OSF patients 
was 14.76±6.45µmol/L. There was significant reduction in mean serum homocysteine 
level in OSF patient after treatment was noted (p=0.003). On comparision of mean pre 
treatment and post treatment serum homocysteine showed statistically significant 
difference. Statistically significant correlation between reduction in serum homocysteine 
and improvement in mouth opening was noted. 
Conclusion: Hence, Serum Homocysteine level may be contributory as a potential 
prognostic marker in treatment of Oral submucous fibrosis. 
Key words: Oral submucous fibrosis, Homocysteine, Inflammation, Potentially 
malignant disorder, Premalignant condition 
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INTRODUCTION 
Homocysteine is a sulphur containing aminoacid formed during methionine 
metabolism during the conversion of methionine to cysteine. Du Vigneud an American 
biochemist in the early 1930’s discovered a structure similar to cysteine with an extra 
carbon atom and named it as homocysteine. It was studied for many years only in context 
with the hereditary disease homocystinuria1. 
Clinical researches done over the last decade has shown that elevated levels 
of homocysteine have been identified as an independent risk factor for atherosclerosis, 
cardiovascular disease, cerebrovascular disease, renal disease, ischemic optic neuropathy 
and cancer2. Various studies done in oral mucosal diseases such as oral lichen planus3, 
burning mouth syndrome4, atrophic glossitis5, recurrent aphthous stomatitis6, Behcets 
disease7 and head and neck cancers8 also reported elevated levels of homocysteine. 
The factors contributing to hyperhomocysteinemia include lifestyle changes 
(vegans, betel nut chewing, smoking, and alcohol), drugs (anti-epileptics) and genetic 
defects (MTHFR polymorphism).The mechanism of action by which homocysteine 
causes disease is complex and not completely understood, but mainly explained on the 
basis of oxidative damage and protein homocysteinylation9. 
Hyperhomocysteinemia exert its detrimental effects through induction of 
acute and chronic inflammation pathway such as endothelial dysfunction, leukocyte 
adhesion, oxidative stress and reduction in nitric oxide bioavailability. It has been 
reported that oxidative stress derived from hyperhomocysteinemia will induce chronic 
inflammation via the regulation of NF-κB transcription factor. Thus it is noted that 
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hyperhomocysteinemia is not only produced from inflammation but also the oxidative 
stress generated from hyperhomocysteinemia will again promote inflammation10.  
Inflammation promotes cell proliferation at the expense of excess amount of 
vitamins and deficiency of folic acid, vitamin B12 and vitamin B6 is reflected as 
hyperhomocysteinemia as they are involved in the metabolism of homocysteine. Thus 
hyperhomocysteinemia indicates the presence of inflammation and indirectly reflects 
vitamin status10. 
Alteration in homocysteine levels may cause imbalance among the products 
of the anti-oxidant pathway resulting in increased oxidative metabolism. Homocysteine 
synthesis is also related indirectly to DNA methylation, a mechanism for gene expression 
control in normal and tumor cells, thus, showing its contribution in carcinogenesis11. 
Schwartz in 1952 described a condition affecting the oral mucosa including 
the palate and faucial pillar, called "atrophia idiopathica (tropica) mucosae oris" among 
five Indian women from Kenya12.  Later the term “Oral submucous fibrosis” was coined 
by S.G Joshi in 195313. Paymaster (1956) observed the precancerous nature of OSF, 
because of the slow onset of squamous cell carcinoma in one third of OSF patients14. 
In 1966 Pindborg and Sirsat, defined OSF as “an insidious, chronic disease 
affecting any part of the oral cavity and sometimes the pharynx. Although occasionally 
preceded by and/or associated with vesicle formation, it is always associated with juxta-
epithelial inflammatory reaction followed by fibroelastic change of the lamina propria, 
with epithelial atrophy leading to stiffness of the oral mucosa and causing trismus and 
inability to eat”15. 
The disease is predominantly seen in southern parts of the subcontinent with a 
reported prevalence ranging up to 0.4% in Indian rural population16.There is increased 
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incidence to 6.42% in the recent years 17. Majority of them belonged to the age group of 
20-40 years of age with male predominance18. The condition has been described as a 
“potentially malignant disorder” in view of the high rate of malignant transformation in 
the range of 7–13% 19. 
The exact etiology of OSF is not well understood. The pathogenesis of the 
disease is believed to be multifactorial. Numerous factors trigger the disease process by 
causing a juxtaepithelial inflammatory reaction in the oral mucosa. These include areca 
nut chewing, ingestion of chillies, genetic and immunologic processes, nutritional 
deficiencies etc. As it is of multifactorial etiology, no satisfactory treatment has been 
described in literature till date.  
Current evidence suggests that arecoline in the areca nut is the key factor in 
initiating the disease20. Areca nut is the fourth most addictive substance in the world. The 
habit of betel quid chewing is widespread throughout India and South East Asia21 and it is 
widely prevalent in teenagers and young adults19. 
The alkaloids and flavonoids (arecoline, arecaidaine, tannins and catechins) 
stimulate collagen synthesis and proliferation of fibroblasts and can act both as chemical 
and physical irritant to oral mucosa. The micro trauma produced by friction of coarse 
fibres of arecanut facilitates diffusion of alkaloids into the subepithelial connective tissue 
resulting in juxtaepithelial inflammatory cell infiltration22. 
The ingredients of arecanut stimulates connective tissue growth factor in 
buccal mucosal fibroblasts through generation of reactive oxygen species (ROS) which 
strongly activate NF-kappa B, JNK and p38 and damages the cell structures23. 
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Moreover vitamin deficiency and malnutrition can derange the repair of the 
inflamed oral mucosa, leading to defective healing and the resulting atrophic oral mucosa 
is more susceptible to the effects of areca nut24. 
Wide ranges of investigations have been carried out in this condition to 
identify the causation and pathogenesis. Biochemical investigations of blood, serum and 
tissues have been the simple, minimally invasive and earliest form of interventions. Such 
investigations have largely helped to localize parameters that predispose to the 
development of the condition, modify its behavior, monitor the response to therapy and 
prognosticate on its progression and malignant transformation potential25. 
Amino acids and their derivatives can be useful ‘molecular/disease markers’ 
as they reflect the protein metabolism, problems related to dietary uptake and aid in 
understanding the metabolic derangements that occur during the pathological processes 
induced by the PMDs. They may help to categorize PMDs, their risk for malignant 
transformation and may aid in its early detection and management26.  
Few studies have shown an association of serum homocysteine in oral 
mucosal diseases, with reports showing positive correlation and elevated homocysteine 
levels. The current study is only a fourth of its kind, to evaluate the serum homocysteine 
levels in OSF and is the first to compare and analyze the serum homocysteine levels 
before and after medical intervention. Thus this study aimed to assess the homocysteine 
levels in various grades of progression of OSF, to compare the levels between the 
different groups before and after medical intervention. Thus this study is intended to 
evaluate whether homocysteine can be used as a therapeutic prognostic marker in oral 
submucous fibrosis patients. 
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AIM AND OBJECTIVE 
AIM: 
 To evaluate the serum homocysteine level as prognostic marker in oral submucous 
fibrosis. 
OBJECTIVE: 
1. To estimate serum homocysteine in patients with oral submucous fibrosis in 
various stages before and after treatment. 
2. To compare the serum homocysteine before and after treatment and assess the 
value of serum homocysteine level as prognostic marker. 
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                                          REVIEW OF LITERATURE 
HISTORY: 
OSF has been well established in Indian medical literature since the time of 
Susrutha, a renowned Indian physician, who described a condition resembling OSF 
under mouth and throat disease as Vidari during the period of 2500-3000 BC. It was 
characterized by “a progressive narrowing of mouth, depigmentation of oral mucosa and 
pain on taking food”15.  
Schwartz (1952)12  for the first time reported a case of “Atrophia Idiopathica 
(Tropica) Mucosae Oris” occurring in five Indian women living in Kenya and described 
blanching and stiffness of the oral mucosa, difficulty in opening the mouth and inability 
to tolerate spicy food. 
Joshi (1953)13 an ENT surgeon described the disease for the first time in 
India and coined the term “Submucous fibrosis of the palate and pillars”. 
Different authors have described oral submucous fibrosis in different names 
as follows: Lal D (1953)27 -“Diffuse oral submucous fibrosis”, Su I.P (1954)28 -
“Idiopathic scleroderma of the mouth”, Behl P.N (1962)29- “Sclerosing stomatitis”, Rao 
A.B.N (1962)30 – Idiopathic palatal fibrosis, Pindborg J.J (1966)15 – Juxta epithelial 
fibrosis, Ramanathan K (1981)31 – Asian Sideropenic Dysphagia. 
The term “oral submucous fibrosis” has been widely accepted over the years 
as it implies the nature of the condition in a simplified form 32. 
DEFINITION: 
Pindorg J.J, Sirsat S.M (1996)15 defined oral submucous fibrosis as, “an 
insidious, chronic disease affecting any part of the oral cavity and sometimes the pharynx. 
Although occasionally preceded by and/or associated with vesicle formation, it is always 
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associated with juxtaepithelial inflammatory reaction followed by fibroelastic change of 
the lamina propria, with epithelial atrophy leading to stiffness of the oral mucosa and 
causing trismus and inability to eat.”  
WHO (1984)33 had subsequently defined OSF as “a slowly progressive 
disease in which the fibrous bands form in the oral mucosa, ultimately leading to severe 
restriction of movement of the mouth, including the tongue.”  
EPIDEMIOLOGY: 
Pindborg JJ et al (1968)16 in their epidemiological survey concluded that 
there is an increased incidence of OSF of about 0.18%-1.2% in urban population when 
compared with 0.04% - 0.4% in rural population. 
Ranganathan K et al (2004) 34conducted a study in Chennai, South India, 
reported a mean age of 32.4±10.4 years and median age of 29 years. The youngest and 
oldest ages of occurrence of OSF in this study was 16 and 76 years in males and 24 and 
57 years in females. The male to female ratio was 9.9:1. 
Ahmad MS et al (2006)35 carried out an etiological and epidemiological 
study in 157 cases of OSF in Patna, Bihar, India over a period of 2 years. Maximum 
number of cases belonged to 21 – 40 years with the youngest recorded case in a 11 year 
old and oldest one being of 54 years of age. 
Hazarey et al (2007)17 conducted a hospital-based cross-sectional study on 
various habit patterns associated with OSF in 1,000 cases in Nagpur, Central India, over 
a 5-year period. the mean age for men was 27.60 ± 9.58 years and for women, 34.78 
±12.21 years and the severity of OSF was more prevalent in women than men even 
though the male: female ratio was 4.9:1. 
Kumar KK et al (2007)36 studied 75 cases of OSF in Chennai, South India 
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and found that half of the study population belonged to the age group of 20-29 years.  
Angadi PV et al (2011)37 carried out a review on 205 cases in southern India 
diagnosed between January 1989 and June 2005 over a period of 16 years. The age range 
was 14 – 78 years, with mean age being 46 years. OSF was most frequent in the age 
range of 21- 30 years (47.8%). The overall male to female ratio was around 11:1 with a 
general trend towards male preponderance. 
Nigam NK et al (2014)38 conducted a survey in east, west, north and south 
zones of Moradabad district, Uttar Pradesh for a period of one year among 1000 habitual 
chewers. The prevalence of OSF was found to be 6.3% with a male to female ratio of 
6.88:1.  
Recent epidemiological data indicates that the number of cases of OSF has 
raised rapidly in India from an estimated 2, 50,000 cases in 1980 to 2 million cases in 
1993. The reasons for rapid increase of the disease are reported due to an upsurge in the 
popularity of commercially manufactured areca nut preparations (pan masala) in India. 
There is increased uptake of this habit by young people with male predominance. This 
could be due to the easy availability of the products in all the places with effective price 
and marketing strategies39. 
ETIOPATHOGENESIS: 
Lal DC (1953)27 in his study observed that all cases of oral submucous 
fibrosis gave a history of chewing supari. Supari is the Hindi word of betel nut, which is 
the fruit of areca catechu palm, which is widely available in India. 
Sirsat SM and Khanolkar VR (1962)22 histologically studied the effect of 
arecoline on the palate and buccal mucosa of 20 light wistar rats and found arecoline an 
active ingredient of betel nut played an important role in causation of submucous 
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fibrosis. 
Gupta PC et al (1966)40 stated that oral use of any tobacco product like 
gutkha contain arecanut and several other substances in powdered or granulated form 
which causes oral submucous fibrosis 
Wahi PN et al (1966)41 in their study reported OSF to be higher in patients 
with poor nutritional status. They found that the patients with OSF showed a higher 
frequency of deficiency of vitamin A, B, C and multiple vitamins. 
Phatak AG (1978)42 did a study on 34 patients suffering from OSF and 
observed that these patients had significantly elevated levels of serum globulin and 
immunoglobulin IgG, stating the possibility of OSF being an auto-immune disorder. 
Shiau (1979)43 done a study in 35 OSF cases amongst Chinese in Taiwan and 
observations suggested that betel nut chewing was a significant contributory factor and 
tobacco, hot spicy food and liquor were not important etiologic factors for the occurrence 
of OSF. 
Ramanathan K (1981)31observed a prolonged iron and vitamin B complex 
deficiency in 10 out of 13 submucous fibrosis patients and gave a hypothesis that 
submucous fibrosis could be the Asian version of Siderophenic Dysphagia.  
Caniff JP et al (1981)44 proved that arecanut can act as potent stimulator for 
collagen synthesis in human fibroblast culture leading to excessive accumulation of 
collagen leading to fibrosis. 
Canniff JP et al (1986)45 suggested that the addition of slaked lime to areca 
nut hydrolyses arecoline to arecaidine and the inflamed mucosa had enhanced 
permeability to arecoline and arecaidine. 
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Rajendra R et al (1986)46 in the study compared the cell mediated and 
humoral immune response of 50 oral submucous fibrosis patients with 50 leukoplakia, 50 
oral cancer and 50 normal patients. The number of high affinity rosette forming cells 
(HAFC) was found to be significantly decreased and levels of serum IgA, IgD and IgE 
were found to be elevated both in OSF and oral cancer indicating oral submucous fibrois 
can be intermediary state in the malignant transformation of normal cells. 
 Seedat HA et al (1988)47 studied  the clinical and histological features in 14 
subjects who had given up betel nut chewing 13 years before but these patients had signs 
and symptoms suggestive of OSF. It was the concluded that once OSF was induced by the 
habit of chewing betel nut, the reversal of the disease after cessation of habit did not 
occur. 
Sinor PN et al (1990)48 demonstrated the dose-response relationship 
between degree of exposure and the risk of a disease is an important criterion for causal 
inference. In a case-control study from India, the relative risk increased with the duration 
as well as the frequency of the areca nut chewing habit.  
Jeng JH (1994)49 conducted a study to observe the pathobiological effects of 
aqueous extracts of betel quid constituents.lt showed that betel quid contained not only 
genotoxic and cytotoxic agents but also compounds that had the ability to stimulate 
cellular proliferation. 
Maher R et al (1994)50 from a case control study in Karachi showed that 
daily consumption of pan appeared to have important effect than the duration of habit. 
They suggested that relatively short exposure is sufficient to induce fibrosis in subjects 
who are susceptible to the disease. 
Haque MF et al (1998)51in their immunohistochemical study of oral 
 Review Of Literature 
11 
 
submucous fibrosis showed the increased evidence of CD4 and HLA-DR positive cells 
in oral submucous fibrosis, the presence of these immunocompetent cells and high ratio 
of CD4 to CD8 in oral submucous tissue suggests an ongoing cellular response leading 
to a possible role of immunity in OSF. 
Chaturvedi VN et al (1998)52 studied 18 cases of oral submucous fibrosis 
and concluded that increased level of serum IgG in all grades of oral submucous fibrosis 
suggesting and autoimmune basis of oral submucous fibrosis. 
Trivedy C et al (1999)53 in their study observed that copper is released from 
areca products during chewing and is deposited in oral tissues. They found that 
lysyloxidase activity is upregulated in OSF patients. From these findings they 
hypothesized that cellular events lead to cross linking of collagen and elastin, making 
them less degradable. The up regulation of lysyloxidase in OSF may be an important 
factor in the pathogenesis of this disorder. 
Haque MF et al (2000)54 demonstrated increased levels of proinflammatory 
cytokines and reduced antifibrotic interferon γ (IFN-γ) in patients with oral submucous 
fibrosis which may be the central to the pathogenesis of oral submucous fibrosis. 
Chiang et al (2002)55 showed the betel quid placed in the buccal vestibule for 
about 15 minutes to an hour and repeated 5 to 6 times a day which leads to constant 
contact between the mixture and oral mucosa. The alkaloids from the quid are absorbed 
into the mucosa and undergoes metabolism. Microtrauma produced by the friction of 
coarse fibers of areca nut also facilitates diffusion of the alkaloids into the subepithelial 
connective tissue resulting in juxtaepitheial inflammatory cell infiltration. 
Nair et al (2004)56 showed that continuous local irritation by pan masala, 
gutkha or areca nut can lead to injury related chronic inflammation, oxidative stress and 
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cytokine production. Oxidative stress and subsequent Reactive oxygen species (ROS) 
generation can induce cell proliferation, cell senescence or apoptosis, depending upon 
the level of ROS production. During chronic exposure, these events can lead to 
preneoplastic lesions in the oral cavity and subsequently to malignancy. 
Rajalalitha et al (2005)57 in the review mentioned the initial events in the 
disease process in oral mucosa which is in direct contact with the betel quid due to the 
habit which is the site of constant irritation 
 
Goel et al (2010)58 found that the patients who used pan masala with a greater 
frequency per day developed OSF earlier. Daily consumption was more significant than 
the total duration of the habit. 
Wang YP et al (2015)59 conducted a study in a 68 male OSF patients to 
evaluate anemia, hematinic deficiencies, and serum gastric parietal cell antibody 
(GPCA) positivity and found 7.4%, 20.6%,  50.0%, 41.2%, and  13.2%  had Hb, iron, 
vitamin B12 and folic acid deficiencies, and serum GPCA positivity. 
Tilakaratne et al (2016)23 in the review on the etiology and etiopathogenesis 
of OSF showed the possible biochemical and molecular events known in the pathogenesis 
of OSF 
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CLASSIFICATIONS OF OSF60 
Several classifications based on clinical and histological features, have been put forth by 
various researchers, based on different aspects of OSF. 
A. Classifications based on clinical features of OSF given by: JV Desa (1957),Pindborg 
JJ (1989), SK Katharia et al (1992), Lai DR et al (1995), R Maher et al (1996), 
Ranganathan K et al (2001), Rajendran R (2003), Nagesh and Bailoor (2005), Tinky Bose 
and Anita Balan (2007), Kiran Kumar et al (2007), Chandramani More et al (2011) 
B. Classifications based on histopathological features given by: Pindborg JJ and Sirsat 
SM (1966), Utsunomiya H et al (2005), Kiran Kumar et al (2007) 
C. Classification based on clinical and histopathological features: Khanna JN et al (1995) 
1. Classification based on clinical features of OSF: 
1. JV Desa (1957) divided OSF into three stages as follows: 
Stage I : Stomatitis and vesiculation 
Stage II : Fibrosis 
Stage III : As its sequelae 
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2. Pindborg JJ in 1989 divided OSF into three stages as follows: 
Stage I: Stomatitis includes erythematous mucosa, vesicles, mucosal ulcers,   
melanotic mucosal pigmentation and mucosal petechiae. 
 Stage II: Fibrosis occurs in healing vesicles and ulcers, hallmark of this stage. 
- Early lesions show blanching of the oral mucosa. 
- Older lesions include vertical and circular palpable fibrous bands in the buccal 
mucosa and around the mouth opening or lips. 
- This results in a mottled marble like appearance of the mucosa because of the 
vertical thick, fibrous bands in association with a blanched mucosa. 
- Specific findings include reduction of mouth opening, stiff and small tongue, 
blanched and leathery floor of the mouth, fibrotic and depigmented gingiva, 
rubbery soft palate with decreased mobility, blanched and atrophic tonsils, 
shrunken bud like uvula and sunken cheeks, not commensurate with age or 
nutritional status. 
Stage III: Sequelae of OSF are as follows: 
- Leukoplakia is found in more than 25% of individuals with OSF. - Speech and 
hearing deficit may occur because of involvement of tongue and the Eustachian 
tube. 
3. SK Katharia et al (1992) have given different scores assigned to the patients on the  
basis of mouth opening between upper and lower central incisors as follows 
                Score 0: Mouth opening is 41mm or more, Score 1: Mouth opening is 37 to 40 
mm, Score 2: Mouth opening is 33 to 36 mm, Score 3: Mouth opening is 29 to 32 mm, 
Score 4: Mouth opening is 25 to 28 mm, Score 5: Mouth opening is 21 to 24 mm, Score 
6: Mouth opening is 17 to 20 mm, Score 7: Mouth opening is 13 to 16 mm, Score 8: 
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Mouth opening is 09 to 12 mm, Score 9: Mouth opening is 05 to 08 mm, Score 10: Mouth 
opening is 0 to 04 mm. 
4. Lai DR (1995) divided OSF based on the interincisal distance as follows: 
- Group A: >35 mm 
- Group B: Between 30 and 35 mm 
- Group C: Between 20 and 30 mm 
- Group D: <20 mm  
6. Ranganathan K et al (2001) divided OSF based on mouth opening as follows:  
- Group I: Only symptoms, with no demonstrable restriction of mouth opening. 
- Group II: Limited mouth opening 20 mm and above. 
- Group III: Mouth opening less than 20 mm. 
- Group IV: OSF advanced with limited mouth opening. Precancerous or cancerous 
changes seen throughout the mucosa. 
7. Rajendran R (2003) reported the clinical features of OSF as follows: 
- Early OSF: Burning sensation in the mouth. Blisters especially on the palate, 
ulceration or recurrent generalized inflammation of oral mucosa, excessive 
salivation, defective gustatory sensation and dryness of mouth. 
- Advanced OSF: Blanched and slightly opaque mucosa, fibrous bands in buccal 
mucosa running in vertical direction. Palate and faucial pillars are the areas first 
involved. Gradual impairment of tongue movement and difficulty in mouth 
opening. 
9. Chandramani More et al (2011):  
- Clinical staging: 
- Stage 1 (S1): Stomatitis and/or blanching of oral mucosa. 
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- Stage 2 (S2): Presence of palpable fibrous bands in buccal mucosa and/or 
oropharynx, with /without stomatitis. 
- Stage 3 (S3): Presence of palpable fibrous bands in buccal mucosa and/or 
oropharynx, and in any other parts of oral cavity, with/ without stomatitis. 
- Stage 4 (S4) as follows: 
a. Any one of the above stage along with other potentially malignant disorders, e.g. 
oral leukoplakia, oral erythroplakia, etc. 
b. Any one of the above stage along with oral carcinoma. 
- Functional staging: 
- M1: Interincisal mouth opening up to or greater than 35 mm. 
- M2: Interincisal mouth opening between 25 and 35 mm. 
- M3: Interincisal mouth opening between 15 and 25 mm. 
- M4: Interincisal mouth opening less than 15 mm. 
2. Classifications based on histopathological features of OSF 
1. Pindborg JJ and Sirsat SM (1966) were the first to divide OSF depending only on 
histopathological features alone are as follows:  
- Very early stage: Finely fibrillar collagen dispersed with marked edema. Plump 
young fibroblast containing abundant cytoplasm. Blood vessels are dilated and 
congested. Inflammatory cells, mainly polymorphonuclear leukocytes with 
occasional eosinophils are found. 
- Early stage: Juxta-epithelial area shows early hyalinization. Collagen still in 
separate thick bundles. Moderate number of plump young fibroblasts is present. 
Dilated and congested blood vessels. Inflammatory cells are primarily 
lymphocytes, eosinophils and occasional plasma cells. 
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- Moderately advanced stage: Collagen is moderately hyalinized. Thickened 
collagen bundles are separated by slight residual edema. Fibroblastic response is 
less marked. Blood vessels are either normal or compressed. Inflammatory 
exudate consists of lymphocytes and plasma cells. 
- Advanced stage: Collagen is completely hyalinized. Smooth sheets with no 
separate bundles of collagen are seen. Edema is absent. Hyalinized area is devoid 
of fibroblasts. Blood vessels are completely obliterated or narrowed. 
Inflammatory cells are lymphocytes and plasma cells. 
3. Classification based on clinical and histopathological features 
I. Khanna JN and Andrade NN (1995) developed a group classification system for the 
surgical management of OSF. 
- Group I:- Very early cases: Common symptom is burning sensation in the mouth, 
acute ulceration and recurrent stomatitis and not associated with mouth opening 
limitation. 
- Histology: Fine fibrillar collagen network interspersed with marked edema, blood 
vessels dilated and congested, large aggregate of plump young fibroblasts present 
with abundant cytoplasm, inflammatory cells mainly consist of 
polymorphonuclear leukocytes with few eosinophils. The epithelium is normal. 
- Group II: Early cases—Buccal mucosa appears mottled and marble like, 
widespread sheets of fibrosis palpable, interincisal distance of 26 to 35 mm. 
- Histology: Juxta-epithelial hyalinization present, collagen present as thickened but 
separate bundles, blood vessels dilated and congested, young fibroblasts seen in 
moderate number, inflammatory cells mainly consist of polymorphonuclear 
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leukocytes with few eosinophils and occasional plasma cells, flattening or 
shortening of epithelial rete-pegs evident with varying degree of keratinization. 
- Group III: Moderately advanced cases— Trismus, interincisal distance of 15 to 25 
mm, buccal mucosa appears pale firmly attached to underlying tissues, atrophy of 
vermilion border, vertical fibrous bands palpable at the soft palate, 
pterygomandibular raphe and anterior faucial pillars. 
- Histology: Juxta-epithelial hyalinization present, thickened collagen bundles, 
residual edema, constricted blood vessels, mature fibroblasts with scanty 
cytoplasm and spindle-shaped nuclei, inflammatory exudates which consists of 
lymphocytes and plasma cells, epithelium markedly atrophic with loss of rete 
pegs, muscle fibers seen with thickened and dense collagen fibers. 
- Group IVA: Advanced cases—severe trismus, interincisal distance of less than 15 
mm, thickened faucial pillars, shrunken uvula, restricted tongue movement, 
presence of circular band around entire lip and mouth. 
- Group IVB: Advanced cases—presence of hyperkeratotic leukoplakia and/or 
squamous cell carcinoma. 
- Histology: Collagen hyalinized smooth sheet, extensive fibrosis, obliterated the 
mucosal blood vessels, eliminated melanocytes, absent fibroblasts within the 
hyalinized zones, total loss of epithelial rete pegs, presence of mild to moderate 
atypia and extensive degeneration of muscle fibers. 
CLINICAL SYMPTOMS  
Rao AB (1962)30 noted features like inability to open mouth, intolerance to 
hot spicy food, inability to protrude their tongue and complained of pain in the ear and 
swelling and pain around the lower jaw and neck. Also found when the fibrosis reaches 
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the pharynx, referred pain in the ears and deafness due to occlusion of Eustachian tubes. 
Pindborg JJ and Sirsat (1966)15 in their article noted prodromal symptoms 
like burning sensation for spicy food, blisters and ulceration or recurrent stomatitis, 
defective gustatory sensation, excessive salivation and dryness of mouth on OSF 
patients. 
Hayes (1985)61 reported that the most characteristic feature of OSF is the 
marked vertical fibrous ridge formation within the cheeks, and board like stiffness of the 
buccal mucosa leading to trismus and difficulty in blowing cheeks. 
Murthi PR et al (1992)62 elicited the symptoms of oral submucous fibrosis 
that included trismus, pain and burning sensation on spicy food, altered salivation, 
change in gustatory sensation, hearing loss due to stenosis of Eustachian tubes, nasal 
tone to voice, dysphagia to solids and impaired mouth movements. 
El Labbon et al (1985)63 have investigated the muscle changes 
ultrastructurally in  OSF patients and concluded that restricted mouth opening in OSF 
might be depend upon not only on subepithelial fibrosis, but also on the extent of 
degeneration of masticatory muscle.  
Cox SC and Walker DM (1996)64 in their review stated that the retromolar 
areas and the buccal mucosa were commonly involved, followed by soft palate, palatal 
fauces, uvula, tongue and labial mucosa. The main diagnostic criteria for OSF clinically 
were the presence of fibrous bands. 
Tilakarathne WM et al (2006)65 reviewed about the disease progression 
and sequential disabilities of oral functions like restricted mouth opening, inability to 
blow out a candle or whistle and difficulty in swallowing. They concluded that bands are 
common at the back of the mouth in mild cases of OSF and as the disease increases in 
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severity are more likely to be found anteriorly as well.  
PREMALIGNANT POTENTIAL: 
Paymaster JC (1956)14 was the first to report the precancerous nature of OSF 
in 650 patients and described the development of slow growing squamous cell carcinoma 
in one third of the patients with oral submucous fibrosis. 
Pindborg JJ (1972)66 analyzed 220 biopsies from patients with submucous 
fibrosis for premalignant changes summarized criteria to support the precancerous nature 
of this disease as 
 Higher prevalence of leukoplakia among OSF patients.  
 Higher frequency of epithelial dysplasia.  
 Concurrent findings of OSF in oral cancer patients. 
 Histopathological diagnosis of oral cancer without clinical suspicion 
among OSF cases. 
 Higher rate of incidence of oral cancer among patients with OSF [3] 
Gupta PC et al (1980)67 reported malignant transformation in 2.3% patients 
with OSF in a 10 year follow study in Ernakulum District, Kerala. 
Pindborg JJ et al (1984)68 in an evaluation of malignant potential of 
submucous fibrosis patients after biopsy,12% showed squamous cell carcinoma,26% 
epithelial dysplasia and 76% atrophic epithelium reinforcing the hypothesis that 
submucous fibrosis is a precancerous condition. 
Murti PR et al (1985)19 reported 7.6% malignant transformation rate in a 17 
year follow up study. Oral cancer developed 3-16 years after the diagnosis of submucous 
fibrosis. The average age at the time of malignant transformation was 64.6 years and age 
range was 48-81 years. 
 Review Of Literature 
21 
 
Murti PR et al (1995)69 found on their tissue culture experiments using 
human fibroblasts and suggested that arecanut alkaloids yield powerful carcinogenic 
nitrosamines which explains the malignant potential of OSF. 
Rajendran and Joshy (1998)70 described submucous fibrosis as a 
potentially malignant condition of the oral mucosa characterized principally by epithelial 
atrophy resulting in increased permeability to carcinogen. The disease is initiated in the 
connective tissue and epithelial changes of atrophy and cytological atypia are secondary. 
Recently, the carcinogenicity of areca nut without tobacco was identified, 
and the second IARC monograph on betel quid has classified areca nut as a ‘group one’ 
carcinogen based on epidemiologic and laboratory studies. The strong association of 
areca nut with OSF, its dose-dependent effects and the confirmation of OSF as a 
potentially malignant disease leading to oral cancer provided further evidence for this 
assertion71 
Ray et al (2016)72 in the review showed associations observed in studies 
assessing malignant transformation of oral submucous fibrosis 
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TREATMENT  
The main concern in the condition is the management of trismus and burning 
sensation of the oral mucosa. A large number of treatment modalities have been tried by 
both non surgical and surgical approach. 
I.  Discontinuation of Habit & Counseling73 
The preventive measures should be in the form of discontinuation of habit, 
which can be encouraged through education & advocacy. Affected patients should be 
explained about the disease and its possible malignant potential. Thorough counseling 
should be given for de addiction. 
I1. Medical Management 
Steroids73  
Steroids act as immunosuppressive agents by opposing the action of soluble 
factors released by sensitized lymphocytes following activation by specific antigens. 
Steroids also prevent or suppress inflammatory reactions, thereby preventing fibrosis by 
decreasing fibroblastic proliferation and deposition of collagen. Corticosteroids such as 
hydrocortisone, dexamethasone, triamcinolone and betamethasone have been used in the 
treatment of OSF. 
Enzymes73  
Enzymes such as hyaluronidase, collagenase and chymotrypsin are being used 
for the treatment of OSF. Hyaluronidase breaks down hyaluronic acid, lowers the 
viscosity of the intercellular cement substances and decreases collagen formation. The 
effect is short term, but combination with steroids gives longer-term results. 
Chymotrypsin hydrolyzes ester and peptide bonds, and acts as a proteolytic and anti-
inflammatory agent in the treatment of OSF. 
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Dinesh CG et al (1992)74 suggested that no one treatment modality is 
successful in completely eliminating the disease. In patient with grade III and grade IV 
injectable corticosteroids or hyaluronidase locally is helpful.  
Vitamins, Antioxidants and Minerals73 
The ingredients of betel nut induce excessive reactive oxygen species which 
damages the cell structures, including lipids and membranes, proteins and nucleic acids. 
Moreover vitamin deficiency, iron deficiency anemia, and malnutrition can derange the 
repair of the inflamed oral mucosa, leading to defective healing and the resulting atrophic 
oral mucosa is more susceptible to the effects of areca nut. Antioxidant vitamins stabilize 
and deactivate the free radicals before they attack cells. Vitamins A, B complex, C, D, E 
and minerals like iron, copper and magnesium, when used a standard or adjunct are 
effective in controlling the signs and symptoms of OSF.  
Maher R et al (1997)75 evaluated the efficacy of multiple micronutrient 
supplementation including vitamins A, B complex, C, D and E in 117 patients of 
submucous fibrosis. They noted a significant improvement in symptoms, notably 
tolerance to spicy foods, burning sensation and signs of mouth opening. 
Lycopene is a powerful antioxidant and has a singlet -oxygen-quenching 
ability twice as high as that of beta-carotene and ten times higher than that of alpha-
tocopherol. Patients who received 16 mg of lycopene showed an average increase of 3.4 
mm mouth-opening.. The investigators suggested that lycopene is a safe and reliable drug 
and should be used as a first line of therapy in the initial management of oral submucous 
fibrosis76.  
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Biogenic stimulator24 
Placentrix is an aqueous extract of human placenta that contains nucleotides, 
enzymes, vitamins, aminoacids and steroids. It acts by “biogenic stimulation”. Such 
tissues or their extracts, implanted or injected into the body after resistance to pathogenic 
factors, stimulate the metabolic or regenerative processes, thereby favoring recovery. It 
has no contraindications and the results obtained are found to be lasting. 
Peripheral vasodilator24 
Pentoxifylline have vasodilating properties, suppresses leukocyte function, 
stimulates fibrinolysis, inhibits the production of tumor necrosis factor and T and B cell 
activation. Pentoxifylline 400 mg three times daily, resulted in improvement in mouth 
opening, tongue protrusion, and relief from perioral fibrotic bands. 
Anjum Aara et al (2012)77 studied clinically to evaluate the efficacy of oral 
Pentoxifylline 400mg in  OSF patients in comparison to intralesional injections of 
Dexamethasone (4mg/ml) and Hyaluronidase 1500 IU in the management of OSF 
patients. He concluded that Pentoxifylline can be safer and better alternative in the 
treatment of oral submucous fibrosis in comparision to dexamethasone. 
Combined Therapy73 
Vitamin D, E & B complex, placental extract, local & systemic corticosteroids & 
physiotherapy claim a high success rate in oral submucous fibrosis management. 
Other Drugs 
Interferon-Gamma73 
IFN-gamma is a known anti-fibrotic cytokine. Patients treated with an intra-
lesional injection of IFN-gamma experienced improvement of symptoms. 
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Immune milk 
Tai et al (2001)78 studied the Immune milk treatment in OSF patients. The 
immune milk contains an anti-inflammatory component that may suppress the 
inflammatory reaction and modulate cytokine production. Symptomatic relief in patients 
may be partially attributed to the micronutrients contained in the immune milk powder.  
Ayurvedic therapy73 
Administration of turmeric powder offers protection against benzopyrene 
induced increase in micronuclei in circulating lymphocytes and it is an excellent 
scavenger of free radical in vitro. Turmeric oil & turmeric oleoresin both act 
synergistically in vivo to offer protection against DNA damage. 
Deepa Das et al79 found that turmeric dispensed in the form of cucurmin and 
turmeric oil was effective in the treatment of OSF which was evident by the positive 
changes observed in the histopathological examination after treatment along with the 
significant improvement in clinical signs and symptoms.  
Oral Physiotherapy73 
Muscle stretching exercises for the mouth may be helpful to prevent further 
limitation of mouth movements. This includes forceful mouth opening with the help of 
sticks, ballooning of mouth, hot water gargling. This is thought to put pressure on fibrous 
bands. Forceful mouth opening have been tried with mouth gag & acrylic surgical screw. 
Cox and Zoellner (2009)80 advocated five times daily physiotherapy by inter-
positioning tongue spatulas between teeth and adding a new spatula every 5–10 days for 4 
months and observed improved oral opening. 
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Surgical Treatment73 
Surgical treatment is indicated in patients with severe trismus and/or biopsy 
results revealing dysplastic or neoplastic changes. It includes simple excision of the 
fibrous bands, with major limitation being contracture of the tissue and exacerbation of 
the condition.LASER - CO2 laser surgery offers advantage in alleviating the functional 
restriction. 
Cryosurgery73 
It is the method of local destruction of tissue by freezing it in situ. Extreme 
cold is produced by liquid nitrogen or argon gas to destroy abnormal tissue. Liquid sprays 
are better suited for mucosal lesion.  
HOMOCYSTEINE 
Homocysteine is sulfur containing non-protein amino acid, derived from 
methionine an essential amino acid. It was discovered as early as in 1930s by Du 
Vigneaud, an American biochemist who named it Hcy, as its structure was found to be 
similar to cysteine with an extra carbon atom1.Hcy exists in different forms, namely Hcy 
homocystine, Hcy dimer, Hcy thiolactone and Hcy adducts forming the total Hcy9. 
Hcy plasma levels can be measured by enzyme assays, enzyme-linked 
immunosorbent assay (ELISA) and high performance liquid chromatography (HPLC)2. 
Usually the tHcy levels are measured. The normal plasma tHcy is about 5-15µmol/L. 
Hyperhomocysteinemias are graded as follows: Mild 15-30 µmol/L, Moderate 30-
100µmol/L, Severe >100µmol/L. Hcy levels above 50 µmol/l is thought to be a risk 
factor for recurrent heart attacks and a value between 150 and 200 µmol/L may cause 
ischemic stroke. Levels >300 µmol/L may induce mental deficiency9. 
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METABOLIC PATHWAY OF HOMOCYSTEINE 
The only source of Hcy in the body is methionine. Hcy can enter into 2 
pathways. One is the remethylation pathway that depends on vitamin B12 to form 
methionine and the other the trans-sulfuration pathway that depends on vitamin B6 to 
form cysteine. Under normal conditions, most of the Hcy is remethylated back to 
methionine or converted into cysteine by the trans-sulfuration pathway. Three B complex 
vitamins are involved in Hcy metabolism viz. B6, folate or B9, and B12. Deficiency of 
these vitamins and enzymes involved in the metabolism increases plasma Hcy levels9. 
The elevated serum concentration of total homocysteine (Hcy), a well-known 
cardiovascular risk factor, and consequent deficiency of folate, vitamin B12, or vitamin 
B6, or genetic polymorphisms involves the transfer of one-carbon groups. The 
mechanism has been considered critical for Hcy metabolism in carcinogenesis in terms of 
DNA synthesis, repair and methylation81. 
 
Flow diagram of Homocysteine Metabolism 
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FACTORS AFFECTING HOMOCYSTEINE 
Hcy levels in general are found to be higher in men, postmenopausal women, 
in those with increased muscle mass and in the elderly. Smoking, excess alcohol (chronic 
alcoholics, intoxication) and coffee consumption (>5 cups/day), Vegans (those who do 
not consume eggs and milk) are known to cause HHcy. All these factors may affect the 
remethylation pathway thus raising Hcy levels. Antiepileptics like phenytoin, 
phenobarbitone and valproate, others like metformin, raise plasma Hcy levels.9. 
Martha Savaria et al (2000)82 showed that total serum HCY concentrations 
of premenopausal women of all ages were statistically significantly lower than those of 
comparably aged men. Moreover, they found higher plasma homocysteine concentrations 
in postmenopausal versus premenopausal women. 
Chao MC et al (2013)83 reported that subjects with elevated homocysteine 
levels were more likely to be betel nut chewers compared to subjects with normal 
homocysteine levels. 
MECHANISM OF HYPERHOMOCYSTEINEMIA INDUCED DAMAGE9 
The mechanism of action of Hcy in causing ill health and disease appears to 
be complex and not clearly known. The various manifestations of HHcy are explained on 
the basis of oxidative damage and protein homocysteinylation. 
1. Oxidative Damage 
Hcy (with –SH group) continuously gets oxidized resulting in homocysteine 
(S–S group) and homocysteinylated proteins. This leads to the formation of reactive 
oxygen species (ROS) such as super oxide, hydrogen peroxide and hydroxyl free radicals 
leading to damaging effects on biomolecules. 
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2. Protein Homocysteinylation 
Hcy thiolactone is highly reactive and acylate free amino groups of different 
proteins under physiological conditions. The process referred as N–homocysteinylation. 
The degree of protein homocysteinylation increases with increased plasma tHcy and 
largely contributes to manifestations of Hcy toxicity. Homocysteinylated proteins may 
become inactive or result in modified proteins that are detrimental to health. 
Homocysteinylation causes immune activation, autoimmune inflammatory response, 
cellular toxicity and cell death, and enhanced protein degradation. 
ASSOCIATION WITH MARKERS OF ACUTE AND CHRONIC 
INFLAMMATION10 
The oxidative stress derived from hyperhomocysteinemia will again induce 
acute and chronic inflammation via the regulation of NF-κB transcription factor. 
Investigators have failed to reduce the level of inflammation markers when they had 
successfully lowered the level of circulating homocysteine with the administration of 
vitamins. Thus concluded that long as the risk factor (s) is not removed, it would continue 
to generate acute and chronic inflammation regardless whether of deficiency or not. 
                            
Hofmann et al (2001)84 proposed that Hyperhomocysteinemia has often 
been associated with inflammation and Homocysteine has been identified as a 
contributor to four fundamental mechanisms of disease: thrombosis oxidant stress, 
apoptosis and cellular proliferation. 
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Papatheodorou et al (2007)85 proposed that homocysteine (Hcy) induces 
inflammation, possibly by enhancing oxidative stress and subsequent nuclear factor 
kappa B (NfκB) activation. 
MEASURES OF PREVENTION  
Kim and Pae (1996)86 showed that the toxic influence of homocysteine to 
the endothelium can be blocked by antioxidant enzyme supplementation. 
Uppala et al (2012)9 summarized the measures on prevention of 
hyperhomocysteine such as consuming healthy nutritious foods rich in folate, cobalamin 
and pyridoxine. Lifestyle changes like abstaining from smoking and alcohol and reducing 
coffee consumption. Vitamin supplements like Folic acid B9, B12 to lower Hcy levels 
HOMOCYSTEINE AND SYSTEMIC DISEASE9 
Hcy induces oxidative stress resulting in increased production of 3-hydroxy 3-
methyl glutaryl coenzyme A (HMG CoA) in the endothelial cell that leads to increased 
cholesterol production.. An increase by 1 µmol/l of plasma Hcy increases the risk of 
cardiovascular disease by 10%. 
HHcy is implicated in ocular vascular disease. It is associated with retinal 
artery occlusion, diabetic retinopathy, age related macular degeneration, choroidal 
neovascularization, and glaucoma. 
It causes cerebral ischemia leading to cerebrovascular accidents. Methyl 
malonic acid is neurotoxic and the symptoms range from mild irritability, mood swings, 
and forgetfulness to depression and dementia. Alzheimer’s dementia is associated with 
amyloid precursor protein and neurofibrillary tangles, which are due to improper gene 
expression caused by deficient DNA methylation. 
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In diabetes mellitus (DM), HHcy associated microvascular complications 
accelerates atheroscleropathy by endothelial damage induced by oxidative stress. It was 
also found that HHcy is associated with insulin resistance. 
Hyperhomocysteinemia is seen in end stage renal disease. HHcy causes 
endothelial dysfunction and damage to glomerular endothelial cell through oxidant stress. 
HHcy is also associated with an increased risk of fractures. It is hypothesized 
that increase in plasma Hcy levels prevent the formation of collagen cross links. The bone 
matrix is not proper and this leads to fragile bones. The enzyme affected is lysyl oxidase 
and its function is impaired due to homocysteinylation. 
Forges et al (2007)87 summarized the damage to the reproductive system 
caused by HHcy in males and females. In males, the increased plasma Hcy level may lead 
to infertility. In females, Hyperhomocysteinemia is also associated with polycystic 
ovarian disease, recurrent pregnancy loss, defective ovulation, improper embryonic 
cleavage and poor implantation.  
HOMOCYSTEINE AND ORAL DISEASES 
Gonul M et al (2009)88 conducted a study in 45 Bechets disease and 47 
recurrent aphthous stomatitis patients to compare the homocysteine levels and observed 
significantly higher homocysteine levels in BD compared but homocysteine levels in 
RAS patients were not significantly different from those of healthy controls. 
Sun A et al (2012)5 conducted a study in 176 atrophic glossitis patients and 
found significant association of deficiency of hemoglobin, iron and vitamin B12, 
abnormally high blood homocysteine level, and serum GPCA positivity with AG. 
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Sun A et al (2012)89 conducted a study in 91 atrophic glossitis patients to 
evaluate whether supplementation of different vitamins and iron could reduce the serum 
homocysteine levels and found significant reduction in homocysteine levels. 
Lin HP et al (2013)4 conducted a study in 399 Burning Mouth Syndrome 
patients to evaluate association of hematinic deficiencies and high blood homocysteine 
levels with burning mouth syndrome  and found 89 (22.3%)  had abnormally higher blood 
homocysteine level. 
Sun A et al (2013)90 conducted a study in 399 patients with burning mouth 
syndrome. They were treated with vitamin supplements and found complete remission of 
oral symptoms with significant reduction in serum homocysteine levels. 
Chen HM et al (2015)3 conducted a study in 352 Oral Lichen Planus patients 
to assess association of the deficiencies of hemoglobin (Hb), iron, vitamin B12, and folic 
acid and high blood homocysteine level and found abnormally elevated blood 
homocysteine level than healthy control participants and concluded that there is a close 
relation of high blood homocysteine level to severity of OLP. 
Sun A et al (2015)6 conducted a study in 273 RAS patients and demonstrated 
significantly greater frequencies of Hb, serum iron, vitamin B12, and folic acid 
deficiencies and high serum homocysteine level (7.7% )than healthy control subjects. 
Chang JYF et al (2015)91 conducted a study in 149 oral mucosal disease 
patients with both vitamin B12 and iron deficiencies to evaluate anemic status, MCV, 
serum and found 44 (29.5%) had abnormally higher blood homocysteine level. 
Chang JYF et al (2016)92 in the study assessed hematinic deficiencies and 
anemia statuses in 92 antigastric parietal cell antibody positive Erosive Oral Lichen 
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Planus patients with Desquamative Gingivitis and had found 37 (40.2%) abnormally high 
blood homocysteine level than healthy control individuals. 
Wu YC et al (2016)93 conducted a study in 160 RAS with atrophic glossitis 
patients and 195 RAS without atrophic glossitis patients and found that both had 
significantly greater frequencies of Hb, serum iron, vitamin B12, and folic acid 
deficiencies and of high serum homocysteine level than healthy control subjects. 
HOMOCYSTEINE AND CARCINOMA 
Refsum et al (1991)94 conducted a study in 12 children with acute 
lymphoblastic leukemia found increased tHcy in seven children even before the 
beginning of any treatment and elevated circulating tHcy fell drastically within a few 
days after treatment with cytotoxic drugs. Thus the circulating tHcy reflected the total 
burden of malignant circulating leukemic cells. 
Wu LL and Wu JT (2002)95 in the study found elevated circulating total 
homocysteine (tHcy) in cancer patients even though they were not treated with antifolate 
drugs and the change coincided with the concentration of tumor markers in patients 
undergoing treatment Thus tHcy may be used as a more accurate tumor marker for 
monitoring cancer patients during treatment and hyperhomocysteinemia as a risk factor 
for carcinogenesis. 
Sun CF et al (2002)96 employed tissue cultures of specimens from breast, 
ovarian and pancreatic carcinoma to compare both the Hcy released and production of 
tumor markers between tumor and normal cell lines and detected much higher 
concentrations of Hcy released by the tumor cells. Serum Hcy may be a potentially useful 
tumor marker to monitor tumor activity. 
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Almadori et al (2002)97analyzed serum concentrations of two metabolites 
,folate and homocysteine, in 42 patients affected by head and neck squamous cell 
carcinoma (HNSCC) in comparison with control groups. The results were statistically 
significant. The differences in serum levels of folate and homocysteine might arise from 
tumor development and consequent metabolic alterations or might precede and promote 
tumor progression. 
Almadori (2005)98 In the study on 144 untreated patients with HNSCC and 
40 untreated patients with laryngeal leukoplakia compared with control group. The found 
that serum homocysteine levels in patients with HNSCC were significantly higher 
compared with laryngeal leukoplakia that did not differ significantly from the controls. 
These exclude the role for a high homocysteine serum level both as a risk marker and 
marker of neoplastic progression. 
Eleftheriadou et al (2006)8 measured the serum levels of folate and 
homocysteine in 150 patients with histologically proven SCCHN before any treatment 
and in 150 healthy volunteers. The study indicated a positive correlation between 
hyperhomocysteinemia and hypofolatemia and the presence of SCCHN. 
Ozkan et al (2007)99 conducted a study in newly diagnosed 37 untreated lung 
cancer patients and compared with healthy controls found there were significantly higher 
(t-Hcy) and lower folate levels in the advanced-stage group compared with controls. 
Gorgulu et al (2010)100 in the study to evaluate the role of serum 
homocysteine, folate, and vitamin B12 levels in the pathogenesis of laryngeal squamous 
cell cancer (LSCC) by measuring serum levels in 60 consecutive untreated patients with 
LSCC and 60 controls. There were no significant differences in the homocysteine levels 
between these three groups. 
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Ierardi et al (2013)11 evaluated the serum Homocysteine and Cysteine as a 
biomarkers of disease progression in breast tumor A significant difference was observed 
between pre- and post-treatment levels of Homocysteine and Cysteine in advanced 
tumors, suggesting a prognostic role in patients with poor clinical characteristics. The 
research suggested that Hcy might be used as a prognostic biomarker for breast cancer. 
Zhang et al (2015)81 in the meta-Analysis of 83 Case-Control Studies 
Involving 35,758 Individuals covered more than 14 types of cancer and concluded that  
High level of Hcy but low level of folate was associated with risk of cancer overall, with 
little effect by type of cancer or ethnicity. 
Fanid et al (2015)101 in the prospective study, The European Prospective 
Investigation into Cancer and Nutrition recruited 385,747 participants from 10 countries 
who donated a blood sample. The study included 516 cancer cases of the head and neck 
and esophagus and 516 individually matched controls. Plasma levels of vitamins B2, B6, 
B9, B12, and methionine and homocysteine were measured. The analysis revealead an 
association between elevated levels of the amino acid homocysteine and increased risk of 
squamous cell carcinoma of the head and neck  
HOMOCYSTEINE IN ORAL SUBMUCOUS FIBROSIS 
Bais et al (2013)102 conducted a cross-sectional study in a newly diagnosed 
50 OSF patients in a tertiary care hospital. The homocysteine level was found to be higher 
among the patients of stage IV (31.02±6.33) than stage III (26.98±8.67) and II 
(25.47±7.72). There was no significant difference in the level of homocysteine by gender 
and clinical staging. 
Narang D et al (2014)103 in a study to estimate serum homocysteine level in a 
newly diagnosed 50 OSF patients found an increased level in all patients irrespective of 
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gender and age but no statistically significant co-relation was found among clinical stages 
and pathological grading. The study concludes that chronic inflammation in OSF leads to 
hyperhomocysteinemia which could be used to assess the level of severity of disease and 
may be used as prognosticator marker of therapeutic response for treatment of the disease. 
Jaganath et al (2016)26 conducted a study in 50 patients, comprising of 20 
cases each of OSF and OSCC and 10 healthy controls. The plasma homocysteine levels 
were elevated in OSF and OSCC patients as compared to healthy controls. Conversely 
levels in OSCC patients were lower compared to OSF patients. Although statistically 
insignificant, the altered plasma homocysteine level played a vital role in the 
pathogenesis of these conditions as it brings about oxidative DNA damage, initiating 
carcinogenesis. The supplementation with vitamins could act as chemopreventive agents 
in combating hyperhomocysteinemia, arresting the disease progression in OSF and aiding 
in and treatment of OSCC. 
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MATERIALS AND METHODS 
The study was conducted after getting approval from the Institutional Ethical 
Committee. 
Study Centre: 
1. Department of Oral Medicine and Radiology, 
    Tamil Nadu Government Dental College and Hospital,  
     Chennai - 600003. 
 2. Lister Metropolis Healthcare Limited,  
     Nungambakkam,  
     Chennai - 600034. 
Study Population: 
The study population was selected from the outpatient section of Department of 
Oral Medicine and Radiology, Tamil Nadu Government Dental College and Hospital, 
Chennai. Participants who were satisfying the following inclusion and exclusion criteria 
were included in the study. 
Inclusion criteria for cases: 
 Patient with age group of 20 to 50 years and of both gender. 
 Newly diagnosed patients who satisfy the characteristic clinical features of OSF.  
 Patients who are not under any medication for the same. 
 Patients willing to participate in the study. 
Inclusion criteria for controls: 
 Patient with age group of 20 to 50 years and of both gender. 
 Patients willing to participate in the study. 
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Exclusion criteria for cases: 
 Patients with chronic systemic diseases like Cardiac, Cerebrovascular, 
Respiratory, Renal, Hepatic, Gastrointestinal disorders, Collagen disorders, 
Infectious diseases, Bleeding disorders and Diabetes Mellitus and Cancer. 
 Patients who are Pregnant (or suspected to be conceived) and Lactation. 
 Patients under medication for systemic illness (anticonvulsant, antifolate, oral 
hypoglycemic drugs). 
 Patients who are contraindicated for steroids. 
 Patient with oral submucous fibrosis who show malignant transformation. 
 Patients with oral submucous fibrosis who are indicated for surgical 
management. 
 Patients suffering from known systemic nutritional deficiencies. 
 Patients not willing to participate in the study. 
Exclusion criteria for controls: 
 Patients with history of habits.  
 Patients with oral mucosal disease. 
 Patients with known systemic illness or under any medication. 
 Patients who are Pregnant (or suspected to be conceived) and Lactation. 
 Patients not willing to participate in the study. 
Sampling Procedure:  
         Convenient Sampling 
Sample Size: 
          Sample size: 37 [Healthy Controls - 7, OSF Patients - 30] 
Study Design: Prospective Study 
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METHODOLOGY: 
Based on inclusion and exclusion criteria, 37 study subjects comprising of 30 
OSF patients and 7 healthy controls were included in the study. All the participants were 
explained about the need and design of the study, the need for undergoing a thorough 
clinical examination, routine investigations and Serum Homocysteine evaluation as a 
part of the study. The OSF patients were explained about the drug therapy and their 
possible adverse effects. Only those subjects who gave a signed informed consent on an 
institutionally approved document were included in the study. Patients were numbered 
serially as they entered the study. 
Patients were made to sit comfortably on a dental chair. A detailed case 
history of the patient with emphasis on their habits and a brief medical history was taken 
to rule out any possible systemic illness. Then thorough clinical examination was carried 
out wearing sterile hand gloves and mouth mask under artificial illumination. A clinical 
diagnosis of OSF was made based on positive history of chewing arecanut or one of its 
commercial preparation, difficulty in mouth opening, burning sensation on eating spicy 
foods and clinical findings of presence of restricted mouth opening, changes in oral 
mucous membrane such as blanching of oral mucosa and presence of palpable fibrous 
bands. The details were recorded on a structured proforma designed for the study. 
The OSF patients were then graded clinically, according to Khanna JN, 
Andrade NN (1995), 
Grade I:  Very early stage  
Normal mouth opening 
Burning sensation in the mouth  
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Acute ulceration and recurrent stomatitis 
Grade II: Early stage 
Interincisal distance of 26 to 35 mm 
Buccal mucosa appears mottled and marble like  
Widespread sheets of fibrosis palpable and red erythematous patches 
Grade III: Moderately advanced stage 
Interincisal distance of 15 to 25 mm 
Buccal mucosa appears pale firmly attached to underlying tissues  
Atrophy of vermilion border 
Vertical fibrous bands palpable at the soft palate, pterygomandibular      
raphe and anterior faucial pillars 
Grade IVA: Advanced stage 
Severe trismus 
Interincisal distance of less than 15 mm 
Restricted tongue movement  
Presence of circular band around entire lip and mouth 
Thickened faucial pillars, shrunken uvula 
Grade IV B: Advanced with premalignant and malignant changes 
Oral submucous fibrosis and Leukoplakia 
Oral submucous fibrosis and Squamous cell carcinoma 
All the participants in control group and OSF group were subjected to 
Complete Haemogram, urine investigation and Homocysteine evaluation.Before the 
drug administration, 30 OSF Patients were subjected to Tobacco Cessation Counselling 
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(TCC) in the institution and TCC were continued during the progress of the study. Oral 
prophylaxis was also carried out in all these patients before Homocysteine evaluation. 
COLLECTION OF DATA 
Clinical parameters included in the study to evaluate the effectiveness of the 
drugs were burning sensation and mouth opening. 
The intensity of burning sensation was determined using a Visual Analogue 
Scale (VAS) of 0-10 with 10 mm division, where 0 was no burning sensation and 10 was 
worst possible burning sensation. The patients were asked to mark VAS at a point which 
best represented their level of symptoms.  
 
The interincisal mouth opening was measured using divider and scale from 
the mesio-incisal angle of upper central incisor to the mesio-incisal angle of lower 
central incisor and recorded in centimetres. If the corresponding teeth were not present 
contra lateral teeth or adjacent teeth will be considered. 
HOMOCYSTEINE ESTIMATION: 
Blood Sample Collection:  
All the study participants were advised overnight fasting to avoid any dietary 
influence and blood samples were collected during the morning hours. Patients were 
made to sit comfortably on a chair. Tourniquet was then applied above the Antecubital 
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fossa. Venipuncture site located, Median cubital vein was palpated and the area cleansed 
using alcohol wipes. Venipuncture performed using a 23 gauge needle and 5ml of blood 
was withdrawn. Tourniquet was released and the needle was withdrawn. Finger pressure 
was applied over the punctured site using cotton for 5 minutes. 
Blood from the syringe was then transferred to the SST vacutainer tube 
and gently inverted for 5 times to activate clotting. Needle in syringe was destroyed using 
needle destroyer and disposed in a puncture proof container. Patient was checked for any 
bleeding from the site and adhesive bandage was applied.  
Blood sample was labeled and placed in a zip lock bag. Then transferred to 
the transportation box and placed in between the pre-frozen gel pack. The lid was closed 
and transported immediately to the laboratory. The processing and analysis was 
performed at the Lister Metropolis Laboratory [ISO 15189: 2007 certified lab], Chennai. 
Sample Processing: 
Blood was allowed to clot for 20 minutes and centrifuged under 3500 rpm for 
10 minutes. An inert gel at the bottom of the vacutainer tube moves to the serum/clot 
interface during centrifugation, thus providing a barrier between the serum and the clotted 
blood. The barrier gel in SST tubes facilitates rapid separation of serum from cellular 
constituents of blood and thus reduces hemolysis and reduced need for aliquot tubes. The 
test tube was then removed from the centrifuge machine. 
Estimation procedure: 
Homocysteine was measured in the serum samples by a fully automated 
ARCHITECT Homocysteine assay (ARCHITECT i system, ABBOTT Laboratories 
USA). The ARCHITECT Homocysteine assay uses Chemiluminescent Microparticle 
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Immunoassay (CMIA) technology for the quantitative determination of serum 
Homocysteine. 
Before loading the Reagent Kit on the system, the microparticle bottle is 
inverted 30 times to resuspend microparticles that have settled down and septum is placed 
on all reagent bottles. The ARCHITECT Homocysteine Reagent Kit is then loaded on the 
ARCHITECT i System. Calibration and control tests are ordered. Then serum samples are 
loaded and procedure initiated.  
Principle of the procedure is that the bound or dimerised homocysteine 
(oxidized form) is reduced by dithiothreitol (DTT) to free homocysteine, which is then 
converted to S-adenosyl homocysteine (SAH) by the action of the recombinant enzyme S-
adenosyl homocysteine hydrolase (rSAHHase) in the presence of excess adenosine. The 
SAH then competes with acridinium-labeled S-adenosyl cysteine for particle-bound 
monoclonal antibody. Following a wash stage and magnetic separation, pre-trigger and 
trigger solutions are added to the reaction mixture and the resulting chemiluminescence is 
measured as relative light units (RLUs). An indirect relationship exists between the 
amount of homocysteine in the sample and the RLUs detected by the ARCHITECT i 
System optics. Results are obtained by using a 4 Parameter Logistic Curve Fit (4PLC, Y-
weighted) data reduction method by generating a calibration curve. The values are then 
recorded. 
Reference range for Male was 5.46 - 16.20 and for Female was 4.44 - 13.56. 
and expressed in µmol/L. 
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METHOD OF DRUG ADMINISTRATION: 
After Homocysteine evaluation, Grade I OSF patients were given 
supplemental medication of Capsule antioxidant twice daily, Tablet Multivitamin once 
daily and Tablet vitamin B complex twice daily for 6 weeks whereas patients in Grade II, 
Grade III and Grade IV were administered intralesional injection of 0.5ml of local 
anaesthesia with 2ml of dexamethasone twice weekly and supplemental medication for 6 
weeks.  
Composition of Capsule Antioxidant which was used as a supplemental 
medication was - Alpha lipoic acid 50 mg + Beta-carotene 10 mg+ Elemental copper 1 
mg + Elemental selenium 75 mcg + Lycopene 5 mg + Vitamin E 10 IU +Zinc sulphate 
27.45 mg, Tablet Multivitamin – vitamin A 2500IU, vitamin D3 200IU, vitamin B1 2mg, 
vitamin B2 2mg, vitamin B6 0.5mg, vitamin C 50 mg, folic acid 0.2mg, calcium 
pantothenate 1mg, niacinamide 25mg and Tablet Vitamin B complex - vitamin B1 2mg, 
vitamin B2 2mg, vitamin B6 0.5mg, calcium pantothenate 1mg, niacinamide 25mg. 
Patient in Grade I were recalled once in a week whereas patients in Grade II, 
Grade III and Grade IV were recalled twice in a week and evaluated for improvement in 
signs and symptoms such as burning sensation and mouth opening. Final changes in 
burning sensation and mouth opening were recorded after the complete course of 
treatment. 
POST OPERATIVE HOMOCYSTEINE EVALUATION: 
After the course of the treatment, all the patients were subjected to post 
operative Homocysteine evaluation similar to pre-operative evaluation and the values are 
recorded. All the values were statistically analysed and the results were drawn. 
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ARMAMENTARIUM 
Examination of the patient: 
 Electrically operated dental chair 
 Patient’s apron 
 Disposable mouth mask 
 Disposable latex examination gloves 
 Stainless steel kidney trays 
 Mouth mirror 
 Stainless steel probe 
 Tweezer 
 Divider and Metallic scale 
Blood sample collection: 
 A pair of disposable gloves 
 Tourniquet 
 Sterile Alcohol wipes 
 Adhesive bandages  
 Sterile Cotton rolls 
 Sterile 5 ml disposable syringe 
 23 gauge needle of 1” length 
 3.5ml BD SST II Plus Vacutainer tube 
 Gel pack 
 Transportation box 
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Homocysteine Evaluation: 
 Centrifuging machine used at 3500 rpm 
 ARCHITECT i SR 2000 Equipment 
 1L71 ARCHITECT Homocysteine Reagent Kit 
 1L71-01 ARCHITECT Homocysteine Calibrators 
 1L71-10 ARCHITECT Homocysteine Controls 
Drug administration: 
 Sterile 2 ml disposable syringe 
 Topical local anesthetic gel  
 Injection Local anaesthesia  
 Injection dexamethasone 2ml vial  
 Capsule Antioxidant 
 Tablet Multivitamin 
 Tablet Vitamin B Complex 
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Master Chart
MASTER CHART
OSF Group:
S.
No
Age Sex Grade Chewing
Duration
(per year)
Chewing
Frequency
(per day)
Burning Sensation Mouth Opening
(mm)
Homocysteine
(µmol/L)
Pre op Post op Pre op Post op Pre op Post op
1 31 M I 4 3 3 0 42 46 12.6 10.3
2 37 M I 7 4 5 0 45 48 11.3 9.8
3 33 F I 3 2 6 0 39 42 7.2 6.4
4 41 M I 9 3 4 0 36 40 10.2 7.4
5 26 M I 3 4 8 0 41 45 12.3 7.1
6 28 F I 2 2 7 0 42 44 8.2 7.65
7 33 M I 8 3 7 0 37 41 13.0 8.6
8 30 M II 6 2 4 0 30 33 15.7 10.2
9 39 M II 10 4 7 0 26 30 19.2 17.1
10 22 M II 2 3 3 0 32 37 14.7 10.95
11 29 M II 5 2 6 0 35 38 16.8 13.5
12 25 M II 7 3 5 0 29 33 15.3 12.0
13 41 M II 20 3 10 0 28 31 21.0 19.7
14 20 M II 5 4 4 0 32 38 14.1 12.3
15 25 M II 2 5 6 0 31 36 18.7 16.1
16 40 M III 18 3 7 0 19 23 21.6 19.3
17 39 M III 13 2 6 0 24 29 20.4 15.7
18 24 M III 7 8 8 1 18 21 28.3 21.2
19 22 M III 4 5 6 0 25 29 17.3 14.5
20 27 M III 6 3 7 0 16 19 21.2 13.4
21 33 F III 9 2 4 0 24 30 11.4 9.6
22 25 M III 7 5 8 0 20 24 23.1 12.7
23 39 M III 5 6 5 0 19 22 20.2 16.4
24 32 M IV 20 7 10 2 11 13 37.6 28.2
25 20 M IV 6 10 8 0 14 19 40.9 23.1
26 39 M IV 11 15 10 3 10 13 50.8 31.6
27 21 M IV 5 10 8 0 12 15 45.7 24.4
28 29 M IV 7 8 7 0 14 18 38.4 20.9
29 48 F IV 13 3 7 1 13 17 11.4 7.99
30 27 M IV 6 7 6 0 11 15 21.4 14.8
Control Group:
S.No Age Sex Grade Chewing
Duration
(per year)
Chewing
Frequency
(per day)
Burning 
Sensation
Mouth Opening
(mm)
Homocysteine
(µmol/L)
1. 25 M NA NA NA 0 53 7.6
2. 48 M NA NA NA 0 51 10.1
3. 34 F NA NA NA 0 48 6.1
4. 31 M NA NA NA 0 52 7.9
5. 29 M NA NA NA 0 55 7.3
6. 35 M NA NA NA 0 51 8.6
7. 42 M NA NA NA 0 48 11.2
NA – Not Applicable
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STATISTICAL ANALYSIS 
The statistical analysis was done using the computer software program SPSS 
version 22. 
The Normality tests Kolmogorov-Smirnov and Shapiro-Wilks tests results 
reveal that the variables follow Normal distribution. Therefore to analyse the data 
parametric methods are applied. To compare the mean values between groups one way 
ANOVA is applied followed by Tukey’s HSD post hoc tests for multiple pair wise 
comparisons. 
To compare pre and post intervention mean values paired t-test is applied. To 
compare proportions between study and control groups Chi-Square test is applied, if any 
expected cell frequency is less than five, then Fisher’s exact test is used. Pearson 
correlation coefficient is calculated to measure the linear relationship between variables. 
In the present study, p < 0.05 was considered as the level of significance. 
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RESULTS 
A total of 37 study participants comprising of 30 OSF patients and 7 healthy 
controls were included in the study. OSF patients were graded clinically into 4 grades. 
They were Grade I (n = 7), Grade II (n = 8), Grade III (n = 8) and  Grade IV (n = 7). 
AGE DISTRIBUTION 
The age range included in the study was 20-50 years with the mean age of 
31.59 ± 7.588. The mean age being 34.86 ± 7.86 in control group, 32.71 ± 5.12 in Grade 
I, 28.88 ± 7.624 in Grade II, 31.13 ± 7.51 in Grade III, 30.86 ± 9.95 in Grade IV. The 
maximum number of OSF was in the age group of 20 – 30 years (n=15) and minimum 
were in 40 -50 (n = 3) years of age. [TABLE 1, 2] 
GENDER DISTRIBUTION 
Out of 37 subjects enrolled in the study 32 (86.5 %) were males and 5 (13.5) 
were females. In comparision of proportion of study participants, in control group, 6 (85.7 
%) were males and 1 (14.3 %) were females whereas in OSF group, in Grade I, 5 (71.4 
%) were males and 2 (28.6 %) were females, in Grade II, 8 (100 %) were males and 0 
(0.0 %) were females, in Grade III 7 (85.7 %) were males and 1 (12.5 %) were females, in 
Grade IV 6 (85.7 %) were males and 1 (14.3 %) were females. Among the OSF patients, 
a male predilection (n = 28) was observed. [TABLE 3] 
HABITS: 
In the present study, all the OSF patients gave a positive history of arecanut 
chewing in the form of commercial preparation such as pan masala or mawa. The most 
common form of arecanut used was found to be mawa with 80 % (n=24).  
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The frequency of chews per day in OSF patients varied between 2 and 15 per 
day. The mean frequency of chews being 5.14 ± 2.795 per day in Grade I, 6.50 ± 4.30 per 
day in Grade II, 8.13 ± 3.64 per day in Grade III and 9.17 ± 5.40 per day in Grade IV 
respectively. Here, Patients in Grade IV were showed the habit of maximum frequency of 
chews per day. [TABLE 4] 
The duration of habits varied between 2 – 20 years in OSF patients with mean 
duration being 3 ± 0.81 years in Grade 1, 3.38 ± 1.06 years in Grade II, 4.38 ± 2.06 years 
in Grade III and 8.57 ± 3.69 years in Grade IV respectively. Patients in Grade IV were 
found to be with maximum duration of habit. [TABLE 5] 
MOUTH OPENING: 
The average mean mouth opening in control group was 51.14 ± 2.54 mm 
(range 55-48). The mean pre treatment mouth opening in OSF patients was 25.83 ± 10.76 
mm (range 10-45 mm) with 40.29 ± 3.15 mm (range 36 – 45 mm) in Grade I, 30.37 ± 
2.77 mm (range 26-35 mm) in Grade II, 20.62 ± 3.29 mm (range 16 – 25 mm) in Grade 
III and 12.14 ± 1.57 mm (range 10-14 mm) in Grade IV respectively. On comparision 
among control and different grades of OSF patients, these values were found to be 
statistically significant (p<0.001). [TABLE 6] 
The post treatment average mean mouth opening in OSF patients was 29.63 ± 
10.84 mm (range 13-48 mm) with 43.71 ± 2.87mm (range 41-48 mm ) in Grade I, 34.50 ± 
3.16 mm (range 30-38 mm) in Grade II, 24.62 ± 4.17 mm (range 19-30 mm) in Grade III, 
15.71 ± 2.36 mm (range 13-19 mm) in Grade IV respectively. On comparision among 
different grades of OSF patients, these values were found to be statistically significant 
(p<0.001). [TABLE 7] 
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In the present study, on comparison of mean values between the pre treatment 
and post treatment mouth opening in Grade I, Grade II, Grade III, Grade IV OSF showed 
highly significant difference in mouth opening (p<0.001). The mean difference in mouth 
opening was 3.8 ± 0.99 mm. The maximum increase in mouth opening was 6 mm and the 
minimum was 2 mm respectively. [TABLE 8] 
BURNING SENSATION: 
The control group (n =7) had showed no pain/burning score (100%). The 
percentage distribution of pain/burning VAS score before the treatment procedure in 30 
OSF patients were 2 (5.4 %) had mild pain/burning sensation, 12 (32.4 %) had moderate 
pain/burning sensation and 16 (43.5 %) had severe pain/burning sensation. [TABLE 9] 
The percentage distribution of pain/burning VAS score after the treatment 
procedure in 30 OSF patients were 26 (86.7 %) had no pain/burning sensation, 4 (13.3 %) 
had mild pain/burning sensation, 0 (0.0 %) had moderate and severe pain/burning 
sensation. They showed statistically significant reduction (p<0.001) in burning sensation. 
[TABLE 10] 
In the present study, all patients (100 %) in Grade I and Grade II and 7 
patients (87.5 %) in Grade III and 4 patients (57.1 %) showed complete reduction in 
burning sensation after medication whereas 1 (12.5%) patient in Grade III and 3 (42.9 %) 
in Grade IV showed mild persistance of burning sensation after medication. [TABLE 11] 
SERUM HOMOCYSTEINE: 
The mean serum homocysteine level in male and female are 19.82 µmol/L 
and 8.86 µmol/L. The mean serum homocysteine in males was found to be higher than 
the females. [TABLE 12] 
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On comparision of mean pre treatment serum homocysteine in males and 
females, statistically significant difference was noted in Grade I, III and Grade IV 
patients. There was no female patient in Grade III. No statistically significant difference 
noted between males and females in control group. On comparision of mean post 
treatment serum homocysteine in males and females, no statistically significant difference 
noted in Grsde I, Grade III and Grade IV. [TABLE13].  
On comparision between pre and post treatment serum Homocysteine level 
among males patients, statistically significant difference was noted. No statistically 
significant difference among female patients in pre and post treatment Homocysteine 
levels noted [TABLE 14] 
The mean serum homocysteine level in control group was 8.40 ±1.74 µmol/L. 
The mean pre treatment serum homocysteine level in OSF group was 20.67±11.26 
µmol/L. The mean serum homocysteine level in Grade I, Grade II, Grade III and Grade 
IV are 10.69 ± 2.26 µmol/L, 16.94 ± 2.45 µmol/L, 20.44 ± 4.82 µmol/L and 35.17 ± 
13.90 µmol/L respectively. [TABLE 15] 
On multiple comparison of serum homocysteine between control and 4 grades 
of OSF. There was no statistically significant difference in serum homocysteine level 
between control and Grade I and Grade II whereas statistically significant difference in 
serum homocysteine level between control and Grade IV (p<0.001) and Grade III (p = 
0.01) was found. There was no statistically significant difference in serum homocysteine 
level between Grade I and Grade II whereas statistically significant difference in serum 
homocysteine level between Grade I and Grade IV (p<0.001) and Grade III (p = 0.01) 
was found. There was no statistically significant difference in serum homocysteine level 
between Grade II and Grade III whereas statistically significant difference in serum 
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homocysteine level between Grade II and Grade IV (p<0.001) was found. There was 
statistically significant difference in serum homocysteine level between Grade III and 
Grade IV (p =0.001). [TABLE 16] 
Thus the pre treatment mean serum homocysteine levels between control and 
OSF group showed statistically significant difference (p<0.001). The mean serum 
homocysteine concentration was higher in OSF group when compared to control group. 
Among the control group and various grades of OSF, the mean serum homocysteine level 
in Grade IV showed the highest value. Thus with progression of disease from Grade I to 
Grade IV, a statistically significant increase in mean serum homocysteine level was 
observed. 
The post treatment mean serum homocysteine levels in OSF patients was 
14.76 ± 6.45 µmol/L. The mean post treatment serum homocysteine level in Grade I, 
Grade II, Grade III and Grade IV are 8.18 ± 1.44 µmol/L, 13.98 ±3.32 µmol/L, 15.35 ± 
3.70 µmol/L and 21.57 ± 8.02 µmol/L respectively. On comparison, the post treatment 
mean serum homocysteine levels between different grades of OSF group showed 
statistically significant difference (p<0.001). [TABLE 17] 
On multiple comparison of post treatment serum homocysteine between 4 
grades of OSF, there was no statistically significant difference in post treatment serum 
homocysteine level between Grade I Grade II and Grade III whereas statistically 
significant difference in serum homocysteine level between Grade I and Grade IV 
(p<0.001) was found. There was no statistically significant difference in post treatment 
serum homocysteine level between Grade II and Grade III whereas statistically significant 
difference between Grade II and Grade IV (p = 0.02) was found. There was no 
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statistically significant difference in post treatment serum homocysteine level between 
Grade III and Grade IV. [TABLE 18] 
In the present study, comparision of mean pre treatment and post treatment 
serum homocysteine in OSF patients showed statistically significant difference (p<0.001). 
On comparison among the grades of OSF such  Grade I, Grade II, Grade III and Grade IV 
also showed statistically significant difference (p=0.009, p<0.001,p= 0.002 and p=0.002) 
respectively. [TABLE 19, 20] 
The mean difference in serum homocysteine level in Grade I, Grade II, Grade 
III and Grade IV patients after treatment are 2.50, 2.95, 5.08 and 13.60 respectively. 
There was significant reduction in mean serum homocysteine level in OSF 
patient after treatment was noted (p=0.003). The greatest reduction in serum 
homocysteine was noted in Grade IV patients after medical intervention. [TABLE 21] 
Serum homocysteine was compared with variables such as chewing 
frequency, chewing duration and mouth opening using Pearson correlation. No 
statistically significant difference were noted when the serum homocysteine levels were 
correlated with the chewing frequency of habits. Statistically significant difference were 
noted when the serum homocysteine levels were correlated with chewing duration of 
habits (p<0.001).Statistically significant difference were noted when the serum 
homocysteine levels were correlated with pretreatment mouth opening (p<0.001).  
Comparison of improvement in mouth opening and serum homocysteine level after 
treatment was evaluated in all grades of OSF and found highly significant result 
(p<0.001). The serum homocysteine levels were found to be lowering with improvement 
in mouth opening. [TABLE 22] 
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TABLE 1: AGE DISTRIBUTION AMONG CONTROL AND VARIOUS 
GRADES OF OSF 
Age (years) Control Grade I 
Grade 
II 
Grade 
III 
Grade 
IV 
Total 
20-30 2 2 4 5 4 17 
30-40 3 4 4 2 2 15 
40-50 2 1 0 1 1 5 
Total 7 7 8 8 7 37 
 
TABLE 2: COMPARISON OF MEAN AGE BETWEEN CONTROL AND 
VARIOUS GRADES OF OSF 
Group N Mean Std. Dev F-Value P-Value 
Healthy 7 34.86 7.862 
0.615 0.655 
Grade I 7 32.71 5.122 
Grade II 8 28.88 7.624 
Grade III 8 31.13 7.511 
Grade IV 7 30.86 9.957 
Total 37 31.59 7.588 
 
TABLE 3: GENDER DISTRIBUTION AMONG CONTROL AND VARIOUS 
GRADES OF OSF 
Gender 
GRADE 
Healthy Grade I Grade II Grade III Grade IV Total 
n(%) n(%) n(%) n(%) n(%) n(%) 
Male 6(85.7) 5(71.4) 8(100) 7(87.5) 6(85.7) 32(86.5) 
Female 1(14.3) 2(28.6) 0(0) 1(12.5) 1(14.3) 5(13.5) 
Total 7(100) 7(100) 8(100) 8(100) 7(100) 37(100) 
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TABLE 4: COMPARISON OF MEAN CHEWING FREQUENCY 
BETWEEVARIOUS GRADES OF OSF 
Variable Grade Mean Std. Dev F-Value P-Value 
Chewing 
Frequency 
Grade I 5.14 2.795 
1.632 0.206 
Grade II 6.50 4.309 
Grade III 8.13 3.643 
Grade IV 9.71 5.407 
Total 7.37 4.271 
 
TABLE 5: COMPARISON OF MEAN CHEWING DURATION BETWEEN 
VARIOUS GRADES OF OSF 
Variable Grade Mean Std. Dev F-Value P-Value 
Chewing 
Duration 
Grade I 3.00 .816 
9.821 <0.001 
Grade II 3.38 1.061 
Grade III 4.38 2.066 
Grade IV 8.57 3.690 
Total 4.77 3.014 
 
TABLE 6: COMPARISON OF MEAN PRE TREATMENT                    
MOUTH OPENING BETWEEN CONTROL GROUP AND VARIOUS 
GRADES OF OSF 
Variable Group Mean Std. Dev F-Value P-Value 
Pre treatment 
Mouth Opening 
Healthy 51.14 2.54 
223.697 <0.001 
Grade I 40.29 3.15 
Grade II 30.37 2.77 
Grade III 20.62 3.29 
Grade IV 12.14 1.57 
Total 30.62 13.98 
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TABLE 7: COMPARISON OF MEAN POST TREATMENT MOUTH 
OPENING BETWEEN VARIOUS GRADES OF OSF 
 
Variable Group Mean Std. Dev F-Value P-Value 
Post treatment 
Mouth Opening 
Grade I 43.71 2.87 
98.872 <0.001 
Grade II 34.50 3.16 
Grade III 24.62 4.17 
Grade IV 15.71 2.36 
Total 29.63 10.84 
 
TABLE 8: COMPARISON OF MEAN PRE AND POST TREATMENT 
MOUTH OPENING BETWEEN VARIOUS GRADES OF OSF 
 
 n Mean Std. Dev t-Value P-Value 
Mouth opening: Pre 30 25.83 10.76 
20.886 <0.001 
Mouth opening: Post 30 29.63 10.84 
  
 
TABLE 9: COMPARISON OF PRE TREATMENT BURNING SENSATION 
BETWEEN CONTROL GROUP AND VARIOUS GRADES OF OSF 
Pre 
treatment 
Burning 
Sensation 
Grade 
Healthy Grade I Grade II Grade III Grade IV Total 
n(%) n(%) n(%) n(%) n(%) n(%) 
No pain 7(100) 0(0) 0(0) 0(0) 0(0) 7(18.9) 
Mild 0(0) 1(14.3) 1(12.5) 0(0) 0(0) 2(5.4) 
Moderate 0(0) 3(42.9) 5(62.5) 4(50) 0(0) 12(32.4) 
Severe 0(0) 3(42.9) 2(25) 4(50) 7(100) 16(43.2) 
Total 7(100) 7(100) 8(100) 8(100) 7(100) 37(100) 
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TABLE 10: COMPARISON OF POST TREATMENT BURNING 
SENSATION BETWEEN VARIOUS GRADES OF OSF 
 
Post 
treatment 
burning 
sensation 
Grade 
Healthy Grade I 
Grade 
II 
Grade 
III 
Grade IV Total 
n % n % n % n % n % n % 
No pain 0 0 7 100 8 100 7 87.5 4 57.1 26 86.7 
Mild 0 0 0 0 0 0 1 12.5 3 42.9 4 13.3 
Moderate 0 0 0 0 0 0 0 0 0 0 0 0 
Severe 0 0 0 0 0 0 0 0 0 0 0 0 
Total 0 0 7 100 8 100 8 100 7 100 30 100 
 
TABLE 11: PROPORTION CHANGE IN PRE AND POST TREATMENT 
BURNING SENSATION 
Pre  treatment 
Burning 
sensation 
Post treatment Burning sensation 
No pain Mild Total 
n % n % n % 
Mild 2 100 0 0 2 100 
Moderate 12 100 0 0 12 100 
Severe 12 75 4 25 16 100 
Total 26 86.7 4 13.3 30 100 
 
 
TABLE 12: COMPARISON OF MEAN PRE TREATMENT SERUM 
HOMOCYSTEINE BETWEEN MALES AND FEMALES  
 
 Gender n Mean Std. Dev t-Value P-Value  
Homocysteine Male 32 19.8281 11.36486 
2.126 0.041 
Female 5 8.8600 2.43475 
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TABLE 13: GENDERWISE COMPARISON OF MEAN PRE AND POST 
TREATMENT SERUM HOMOCYSTEINE  
 
Grade Variables Gender n Mean Std. Dev t-Value P-Value 
Healthy Homocysteine: 
Pre 
Male 6 8.7833 1.54844 
1.604 0.170 
Female 1 6.1000 . 
Grade I Homocysteine: 
Pre 
Male 5 11.8800 1.13004 
4.717 0.005 
Female 2 7.7000 .70711 
Homocysteine: 
Post 
Male 5 8.6400 1.41527 
1.456 0.205 
Female 2 7.0250 .88388 
Grade II Homocysteine: 
Pre 
Male 8 16.9375 2.45004 
- - 
Female 0 . . 
Homocysteine: 
Post 
Male 8 13.9813 3.32501 
- - 
Female 0 . . 
Grade III Homocysteine: 
Pre 
Male 7 21.7286 3.39299 
2.847 0.029 
Female 1 11.4000 . 
Homocysteine: 
Post 
Male 7 16.1714 3.10576 
1.979 0.095 
Female 1 9.6000 . 
Grade IV Homocysteine: 
Pre 
Male 6 39.1333 9.99713 
2.568 0.050 
Female 1 11.4000 . 
Homocysteine: 
Post 
Male 6 23.8333 5.83872 
2.512 0.054 
Female 1 7.9900 . 
 
TABLE 14: COMPARISON OF PRE AND POST TREATMENT SERUM 
HOMOCYSTEINE AMONG MALES AND FEMALES 
 
Gender Variable N Mean Std. Dev t-Value P-Value 
Male Homocysteine: Pre 26 22.3769 11.11962 
5.665 <0.001 
Homocysteine: Post 26 15.8173 6.27594 
Female Homocysteine: Pre 4 9.5500 2.17486 
2.528 0.086 
Homocysteine: Post 4 7.9100 1.31785 
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TABLE 15: COMPARISON OF MEAN PRE TREATMENT SERUM 
HOMOCYSTEINE BETWEEN CONTOL AND VARIOUS GRADES OF 
OSF 
 
Variable Group Mean Std. Dev F-Value P-Value 
Pre treatment 
Serum 
Homocysteine 
Healthy 8.40 1.74 
17.765 <0.001 
Grade I 10.69 2.26 
Grade II 16.94 2.45 
Grade III 20.44 4.82 
Grade IV 35.17 13.90 
Total 18.34 11.24 
 
 
 
 
TABLE 16: MULTIPLE COMPARISON OF MEAN PRE TREATMENT 
SERUM HOMOCYSTEINE BETWEEN CONTOL AND GRADES OF OSF 
 
Variable Grade 
Mean 
Difference 
P-Value 
Pre treatment Serum 
Homocysteine 
Healthy Grade I -2.28571 0.967 
Grade II -8.53750 0.120 
Grade III -12.03750 0.011 
Grade IV -26.77143 <0.001 
Grade I Grade II -6.25179 0.381 
Grade III -9.75179 0.056 
Grade IV -24.48571 <0.001 
Grade II Grade III -3.50000 0.828 
Grade IV -18.23393 <0.001 
Grade III Grade IV -14.73393 <0.001 
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TABLE 17: COMPARISON OF POST TREATMENT SERUM 
HOMOCYSTEINE BETWEEN CONTOL AND VARIOUS GRADES OF 
OSF 
 
Variable Group Mean Std. Dev F-Value P-Value 
Post treatment 
Serum 
Homocysteine 
Grade I 8.18 1.44 
9.642 <0.001 
Grade II 13.98 3.32 
Grade III 15.35 3.70 
Grade IV 21.57 8.02 
Total 14.76 6.45 
 
 
TABLE 18: MULTIPLE COMPARISON OF POST TREATMENT SERUM 
HOMOCYSTEINE AMONG VARIOUS GRADES OF OSF 
 
Variable Grade 
Mean 
Difference 
P-Value 
Post treatment Serum 
Homocysteine 
Grade I Grade II -5.80268 0.104 
Grade III -7.17143 0.031 
Grade IV -13.39143 <0.001 
Grade II Grade III -1.36875 0.936 
Grade IV -7.58875 0.021 
Grade III Grade IV -6.22000 0.073 
 
TABLE 19: COMPARISON OF MEAN PRE AND POST TREATMENT 
SERUM HOMOCYSTEINE IN OSF GROUP 
 
Variable n Mean Std. Dev t-Value P-Value 
Homocysteine: Pre 30 20.67 11.26 
5.618 <0.001 
Homocysteine: Post 30 14.76 6.45 
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TABLE 20: COMPARISONS OF PRE AND POST TREATMENT SERUM 
HOMOCYSTEINE AMONG VARIOUS GRADES OF OSF 
 
Grade  Variable n Mean Std. Dev t-Value P-Value 
Grade I Homocysteine: Pre 7 10.6857 2.25716 
3.755 0.009 
Homocysteine: Post 7 8.1786 1.44449 
Grade II Homocysteine: Pre 8 16.9375 2.45004 
6.314 <0.001 
Homocysteine: Post 8 13.9813 3.32501 
Grade III Homocysteine: Pre 8 20.4375 4.81692 
4.713 0.002 
Homocysteine: Post 8 15.3500 3.69672 
Grade IV Homocysteine: Pre 7 35.1714 13.89829 
5.141 0.002 
Homocysteine: Post 7 21.5700 8.01671 
 
 
 
 
 
TABLE 21: COMPARISION OF MEAN DIFFERENCE BETWEEN 
PRETREATMENT AND POSTTREATMENT SERUM HOMOCYSTEINE 
BETWEEN DIFFERENT GRADES OF OSF 
 
Variable Group Mean  Std. Dev P-Value 
Pre and Post 
treatment serum 
homocysteine  
Grade I 2.5071 1.76645 
0.003 
Grade II 2.9562 1.32434 
Grade III 5.0875 3.05307 
Grade IV 13.6014 6.99972 
Total 5.9037 5.75534 
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TABLE 22: CORELATION BETWEEN PREAND POST TREATMENT 
HOMOCYSTEINE AND VARIABLES 
 
 
 
 
Homocysteine: 
Pre 
Homocysteine: 
Post 
Chewing Frequency Correlation .301 
- P-Value .106 
N 30 
Chewing Duration Correlation .903 
- P-Value <0.001 
N 30 
Mouth opening: Pre Correlation -.781 -.723 
P-Value <0.001 <0.001 
N 37 30 
Mouth opening: Post Correlation -.764 -.737 
P-Value <0.001 <0.001 
N 30 30 
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DISCUSSION 
Oral submucous fibrosis is a chronic debilitating pre-malignant condition 
affecting millions of individuals worldwide and is most commonly seen in the Asian 
subcontinent with increased prevalence in southern parts of the subcontinent16. In recent 
years, the prevalence has increased to 6.42 % in India17. OSF is classified under oral 
potentially malignant disorders23. Despite extensive research, the etiology of OSF still 
remains largely unknown and the pathogenesis is yet to be completely elucidated. Based 
on clinical, epidemiological and in vitro studies, areca nut chewing is considered as the 
important predisposing factor20. 
The diffusion of ingredients of arecanut can act as physical irritant to oral 
mucosa  leading to injury related chronic inflammation, oxidative stress and cytokine 
production56 and induce juxtaepithelial inflammatory cell infiltration22 . The excessive 
production of free radicals and reactive oxygen species is strongly known to activate NF-
kappa B, JNK and p3823. Moreover vitamin deficiency and malnutrition can derange the 
repair of the inflamed oral mucosa, leading to defective healing24.  
Homocysteine is sulfur containing non-protein amino acid, derived from 
methionine, an essential amino acid1. Amino acids and their derivatives can reflect the 
metabolic derangements that occur during the pathological processes induced by the 
PMDs and cancer26. 
The mechanism of action by which homocysteine causes the disease is 
complex and not completely understood. Hyperhomocysteinemia is known to exert its 
detrimental effects through oxidative damage by formation of reactive oxygen species 
(ROS) and protein homocysteinylation9. The oxidative stress is known to induce acute 
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and chronic inflammation via the regulation of NF-κB transcription factor. Thus 
hyperhomocysteinemia indicates the presence of inflammation10.  
Inflammation is recognized to play a critical role in the pathogenesis and 
progression of all life-threatening diseases and varying degrees of hyperhomocysteinemia 
is detectable in all inflammatory diseases including cardiovascular disease, stroke, renal 
failure and cancer10.  
OSF is chronic mucosal inflammatory disease; hence control of inflammation 
or the factors influencing the inflammatory process form the basis of definitive 
management. The injection of corticosteroids was the most frequently studied medical 
therapy and in many centers it remains the first line of treatment for symptomatic patients 
with OSF39. Numerous studies have proven that management of premalignant lesions 
should include along with cessation of habit. Micronutrient supplementation has also 
proved to be efficacious in the management of oral submucous fibrosis76.  Since no single 
drug has provided complete relief of symptoms in the present study combination of drugs 
used to treat the condition. 
Biochemical investigations have been the simple and earliest form of 
interventions to localize parameters that predispose to the development of the condition, 
monitor the response to therapy and prognosticate on its progression and malignant 
transformation potential25. 
Only few studies have been recorded in the literature to show an association 
of serum homocysteine in oral mucosal diseases, pre malignancies like lichen planus, 
laryngeal leukoplakia and cervical dysplasia and malignancies like carcinomas of breast, 
lung and head and neck. To best of our knowledge, the current study is only a fourth of its 
kind, to evaluate the serum homocysteine levels in OSF and is the first to compare and 
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analyze the serum homocysteine levels before and after medical intervention. Thus, this 
study aimed to assess the homocysteine levels in various grades of progression of OSF, to 
compare the levels between the different groups before and after medical intervention. 
Hence, this study intended to evaluate whether homocysteine can be used as a therapeutic 
prognostic marker in oral submucous fibrosis patients. 
A total of 37 study participants comprising of 30 OSF patients and 7 healthy 
controls were included in the study. OSF patients were graded clinically into 4 grades. 
The mean age of study population was 31.59 ± 7.588. The maximum number of OSF was 
in the age group of 20 – 40 years. Out of 37 subjects, 32 were males and 5 were females. 
Among the OSF patients, a male predilection was observed. This is similar to study by 
Hazarey et al17. 
Areca nut is the fourth most addictive substance in the world. The habit of 
betel quid chewing is widespread throughout India and South East Asia21 and it is widely 
prevalent in teenagers and young adults19. All the OSF patients in the study had a habit of 
arecanut chewing in the form of commercial preparation such as mawa or pan masala. 
Majority of them used mawa which is similar to study by Sinor et al48.  
In OSF patients, the Chewing frequency varied between 2 and 15 per day 
with mean frequency of 5.14 ± 2.795 per day. Patients in Grade IV showed the maximum 
frequency of chews per day. The duration of habit varied between 2 – 20 years with mean 
duration being 3 ± 0.81 years. Patients in Grade IV were found to be with maximum 
duration of habit. The habit variables showed significant correlation to severity to clinical 
grading which is similar to study by Reddy et al104. 
The most important measures of outcome associated with morbidity OSF is 
pain/burning sensation to spicy foods, inability to open the mouth with progression of 
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fibrosis39.In the present study, the control group showed no pain/burning score. The 
percentage distribution of pain/burning VAS score before the treatment procedure in 30 
OSF patients were 5.4 % had mild pain/burning sensation, 32.4 % had moderate 
pain/burning sensation and 43.5 % had severe pain/burning sensation. 
After medical intervention, the proportion change between pre and post 
treatment burning sensation was found to be 86.7 % with no pain and 13.3 % showed 
mild persistance of pain. 100% patients in Grade I and Grade II and 87.5 % patients in 
Grade III and 57.1 % patients in Grade IV showed complete reduction in burning 
sensation whereas12.5% patient in Grade III and 42.9 % in Grade IV showed mild 
persistance of burning sensation. Studies by Gupta et al showed similar results of 82%, 
82% and 51% reduction of burning sensation with biweekly injection of intralesional 
steroids.  
The average mean mouth opening in control group was 51.14 ± 2.54 mm  and 
OSF patients was 25.83 ± 10.76 mm with severe reduction of mouth opening  in Grade IV 
patients. After medical intervention, average mouth opening in OSF patients was 
improved to 29.63 ± 10.84 mm. The mean difference in mouth opening was 3.8 ± 0.99 
mm. On comparision among different grades of OSF patients, these values were found to 
be statistically significant (p<0.001).  
According to Maher R et al75 multiple minerals and micronutrients showed 
significant improvement in mouth opening and reduction of burning sensation. Kumar et 
al76 and showed significant improvement in mouth opening and burning sensation either 
singly with antioxidant lycopene or in association with intralesional steroids. Studies by 
Gupta et al showed reduction of burning sensation and improvement of mouth opening 
with biweekly injection of intralesional steroids.  
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In the present study, the mean serum homocysteine of control and OSF 
patients was 8.40 ± 1.74 and 20.67 ± 11.26. On comparison with mean age, increased 
serum homocysteine was noted in OSF group compared to control group with statistically 
significant difference. The reference range of total Hcy for age of 35 years is 10± 
3.5µmol/L2. This indicates hyperhomocysteinemia in OSF group. Jaganath et al26 
reported homocysteine levels greater than 20µmol/L in all the OSF patients. 
In the present study, no statistically significant difference noted between 
males and females in control group. The mean pretreatment serum homocysteine levels in 
male and female patients are 19.82µmol/L and 8.86µmol/L. The serum homocysteine in 
males was found to be higher than the females. Statistically significant difference was 
noted in Grade I, III and Grade IV patients. There was no female patient in Grade II. 
Results were similar to the studies performed by Bias et al102, Narang et al103 and 
Jaganath et al26. 
On comparison between the control group and various grades of OSF, the 
mean serum homocysteine level in Grade IV showed the highest value. Thus with 
progression of disease from Grade I to Grade IV, a statistically significant increase in 
serum homocysteine level was observed. This is similar to the study by Bias et al102 and 
Narang et al102 who reported higher value in Grade IV than Grade III and Grade II but 
the difference was not found to be statistically significant. Jaganath et al26 reported 
statistically significant difference between stage I and Stage II with gradual increase from 
stage II to stage III. 
The post treatment mean serum homocysteine levels in OSF patients was 
14.76 ± 6.45 µmol/L showed a statistically significant difference (p<0.001). The mean 
difference in serum homocysteine level in Grade I, Grade II, Grade III and Grade IV 
Discussion  
68 
 
patients after treatment are 2.50, 2.95, 5.08 and 13.60 respectively. Thus, greater 
reduction serum homocysteine level after medical intervention was noted.  
Post treatment comparision showed no statistically significant difference in 
level of Hcy between male and female and clinical grading. On comparision between pre 
and post treatment serum Homocysteine level among males patients showed statistically 
significant difference whereas among females patients showed no statistically significant 
difference. This might be due to very few female patients in sample.   
In the present study, serum homocysteine was compared with variables such 
as chewing frequency, chewing duration and mouth opening using Pearson correlation. 
No statistically significant difference were noted with the chewing frequency where as 
chewing duration showed statistically significant difference (p<0.001) with longer 
duration of chewing habit was found to be strongly associated with increased serum 
homocysteine levels. Studies by Jaganath et al26 showed negative correlation with 
chewing frequency and chewing duration. Chao MC etal83 reported elevated 
homocysteine levels in betel nut chewers compared to subjects with normal homocysteine 
levels. 
Serum homocysteine was correlated with the preoperative and postoperative 
mouth opening which showed with improvement in mouth opening, statistically 
significant reduction in levels of serum homocysteine.  
Glucocorticoids cause a reduction in collagen fibres by inhibiting the 
proliferation of fibroblast and act to release cellular proteases to activate the collagenase 
to stimulate the rate of collagen breakdown. They also act by inhibiting the inflammatory 
response39. Regulation and control of NF-kB activation can be a powerful therapeutic 
strategy for inhibiting tumor growth and for reducing the tissue damage that follows the 
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release of inflammatory mediators. Studies have shown the immunosuppressive and anti-
inflammatory actions of glucocorticosteroids are potent inhibitors of NF-kB activation in 
mice and cultured cells105. 
The antioxidant vitamins are employed to stabilize and deactivate the free 
radicals before they attack cells73. Kalikiri PC106 in a review discussed that regardless of 
the cause of hyperhomocysteinemia, most patients derive some benefit from vitamin 
supplementation via the conversion of homocysteine back to methionine or cysteine. 
Homocysteine levels usually decrease after a few weeks of therapy and normalize within 
six to eight week. Several studies have shown that supplementation of dietary folate and 
Vit B12 was efficient in bringing down Hcy levels.  
Ubbink et al107 in a placebo controlled study showed the combination of 
vitamin supplementation was very effective in reducing homocysteine levels. Kim and 
Pae et al in an in vitro study showed that the toxic influence of Hcy can be blocked by 
antioxidative enzyme supplementation. Racek et al86 in a randomized study showed folic 
acid as more effective Hcy lowering agent and antioxidant did not influence Hcy 
concentration but improved antioxidative defence. Sun A et al (2013)90 conducted a 
study in 399 patients with burning mouth syndrome. They were treated with vitamin 
supplements and found complete remission of oral symptoms with significant reduction 
in serum homocysteine levels. Sun A et al (2012)89 conducted a study in 91 atrophic 
glossitis patients to evaluate whether supplementation of different vitamins and iron could 
reduce the serum homocysteine levels and found significant reduction in homocysteine 
levels. 
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SUMMARY 
Oral submucous fibrosis is a common pre-malignant condition affecting the 
oral mucosa with more prevalence among Indian population. Biochemical investigations 
are the simple and earliest form of interventions to localize parameters that predispose to 
the development of the condition, monitor the response to therapy and prognosticate on 
its progression. Homocysteine is a non essential amino acid and altered levels noted in 
various mucosal disease and head and neck cancers. The study was conducted to evaluate 
serum homocysteine level as a therapeutic prognostic marker in oral submucous fibrosis. 
To the best of our knowledge, the current study is only a fourth of its kind, to 
evaluate the serum homocysteine levels in OSF and is the first to compare and analyze 
the serum homocysteine levels before and after medical intervention. 
A total of 37 study participants comprising of 30 OSF patients and 7 healthy 
controls were included in the study. After clinical examination, OSF patients were graded 
clinically into 4 grades. All the participants in control group and OSF group were 
subjected to Homocysteine evaluation. OSF patients in Grade I stage were given 
supplemental medication whereas patients in Grade II, Grade III and Grade IV were 
administered intralesional injection of steroids twice weekly with supplemental 
medication for 6 weeks. Patients were evaluated for improvement in signs and symptoms 
such as burning sensation and mouth opening and were recorded after the complete 
course of treatment. All the patients were subjected to post operative Homocysteine 
evaluation and the values are recorded. All the values were statistically analysed and the 
results were drawn. 
The results revealed that the mean homocysteine was higher in OSF group 
compared to control group. On comparision among different grades of OSF patients, 
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these values were found to be statistically significant. The mean homocysteine in males 
was higher than females. The homocysteine level was higher in Grade IV. With 
progression of disease from Grade I to Grade IV, a statistically significant increase in 
mean serum homocysteine level was observed. There was significant reduction in mean 
serum homocysteine level in OSF patient after treatment was noted. On comparision of 
mean pre treatment and post treatment serum homocysteine showed statistically 
significant difference.  
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CONCLUSION 
The present study was conducted to evaluate the serum homocysteine level in 
patients with oral submucous fibrosis in various stages before and after medical 
intervention and to compare and assess the serum homocysteine level as prognostic 
marker in Oral Submucous Fibrosis. 
In the study, serum homocysteine level was higher in OSF group when 
compared to control group with statistically significant differences. Longer duration of 
chewing habit showed increased serum homocysteine levels. Serum homocysteine level 
in Grade IV showed the highest value. Thus, with progression of disease from Grade I to 
Grade IV, a statistically significant increase in serum homocysteine level was observed. 
After medical intervention, there was statistically significant reduction in 
serum homocysteine levels in all the grades of OSF. Statistically significant correlation 
between reduction in serum homocysteine and improvement in mouth opening was noted. 
However, there was no significant correlation between Homocysteine and burning 
sensation. On comparison between the pretreatment and post treatment, statistically 
significant difference in serum homocysteine level was noted in all the grades of OSF.  
So, Serum Homocysteine level may be contributory as a potential prognostic 
marker in treatment of Oral submucous fibrosis. 
However, studies with larger sample size are needed to reinforce the findings 
of our study. We have not included Grade IV B - Advanced stage with premalignant and 
malignant changes such as Oral submucous fibrosis with Leukoplakia and Squamous cell 
carcinoma and future studies including Grade IV B may prove more helpful in throwing 
more light on serum Homocysteine as a prognostic marker in the treatment of Oral 
submucous fibrosis. 
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Appendix 
 
  
                                PATIENT INFORMATION SHEET 
                   I, Dr. M. Gayathri, II year MDS student, Department of Oral Medicine And 
Radiology, primary investigator under the guidance of Prof. Dr. G.V. Murali Gopika 
Manoharan, MDS, Professor, Department of Oral Medicine And Radiology, Tamil Nadu 
Government Dental College and Hospital, have planned to conduct a study titled 
“Evaluation of Serum Homocysteine as Prognostic Marker of Oral Submucous Fibrosis” 
in Tamilnadu Government Dental College and Hospital, Chennai – 3 
 
Purpose of the study  
We are conducting this study to estimate and compare the serum homocysteine levels in 
patients with oral submucous fibrosis in various stages before and after treatment. 
 
Procedures 
Complete medical history, oral cavity examination and blood investigation will be 
done.Blood sample is collected by vein puncture above the antecubital fossa and 3ml of 
blood is withdrawn.It is then sent to laboratory for evaluation of serum homocysteine 
level.Treatment with intralesional injection of 2ml of dexamethasone and 0.5ml of 
lignocaine is administered at single site bilaterally on buccal mucosa twice weekly for six 
weeks and commercially available antioxidant medication will be given.After 6 weeks of 
treatment, blood sample are again collected and sent to laboratory for  evaluation of 
serum homocysteine. 
Benefits of participation 
1.Treatment for oral submucous fibrosis will be given. 
2.If positive results are obtained from this study, estimation of serum homocysteine will 
be useful in judging the prognosis 
 
Participant’s rights 
Taking part in this study is voluntary. Patients are free to decide whether to participate in 
this study or to withdraw at any time; patients decision will not result in any loss of 
benefits to which you are otherwise entitled.The results of this special study may be 
intimated to patient at the end of the study period. 
 
  
Risk of participation 
Participants are selected based on proper inclusion and exclusion criteria and patients who 
are contraindicated to steroids are excluded.The most common currently used medical 
treatment of oral submucous fibrosis is intralesional injection of 2ml of dexamethasone 
with 0.5ml of lignocaine and no complications have been encountered.There is risk of 
candidiasis,transient decreased immunity and weight gain,acneiform skin eruptions and 
hyperglycemia which is informed to the patient prior to obtaining their consent.If any 
adverse effect occurs during the course of treatment,immediate proper treatment will be 
provided. 
 
Confidentiality 
The identity of the patients participating in the research will be kept confidential 
throughout the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared.  
 
Compensation    
Nil 
 
Contacts for queries related to the study: 
          Dr.M.Gayathri, 
II year PG student, 
            Dept of Oral Medicine and Radiology, 
Tamilnadu Government Dental College, 
Chennai 600003 
Phone No 9444820486 
 
Name of the Patient                                                         Signature /Thumb impression 
 
Name of the investigator                                                 Signature 
 
 Date 
Appendix 
 
  
 
                                                  Informed Consent Form 
“Evaluation of Serum Homocysteine as Prognostic Marker of Oral Submucous 
Fibrosis” 
                                                                                Participant ID No:  
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered 
to my satisfaction. I consent voluntarily to participate as a participant in this study and 
understand that I have the right to withdraw from the study at any time without in any 
way it affecting my further medical care.” 
     
Date  Name of the 
participant 
 Signature/thumb impression of 
the participant 
 
[The literate witness selected by the participant must sign the informed consent form. 
The witness should not have any relationship with the research team; If the participant 
doesn’t want to disclose his / her participation details to others, in view of respecting 
the wishes of the participant, he / she can be allowed to waive from the witness 
procedure (This is applicable to literate participant ONLY). This should be documented 
by the study staff by getting signature from the prospective participant] 
________________________________________________________________________
________________________________________________________________________
______________ 
“I have witnessed the accurate reading of the consent form to the potential 
participant and the individual has had opportunity to ask questions. I confirm that the 
individual has given consent freely” 
 
Date  Name of the witness  Signature of the witness 
 
 
Date  Name of the 
interviewer 
 Signature of the interviewer 
 
 
  
                      DEPARTMENT OF ORAL MEDICINE AND RADIOLOGY     
TAMIL NADU GOVT. DENTAL COLLEGE & HOSPITAL, CHENNAI -3   
CASE PROFORMA 
EVALUATION OF SERUM HOMOCYSTEINE AS PROGNOSTIC MARKER OF 
ORAL SUBMUCOUS FIBROSIS 
 
Date:                                                                            Serial no: 
Name:                                                                          O.P No: 
Age/Sex: 
Address: 
 
Phone no: 
Occupation:                                                                Income: 
Religion: 
Centre:      Department of Oral Medicine And Radiology, 
      Tamil Nadu Govt Dental College & Hospital, Chennai -3 
Presenting complaint with duration: 
 
Past medical history: 
 
Past Surgical history: 
 
Past dental history: 
 
  
Personal history: 
A) Diet: 
 
B) Teeth cleansing habits: 
 Cleaning aids used: 
 Frequency              : 
 
C) Smoking habit: 
 Material used: 
 Frequency      : 
 Duration of the habit: 
 
D) Chewing habit: 
 Material used: 
 Frequency      : 
 Duration of the habit: 
 
E) Other habits (alcohol, snuff): 
 
Marital status: 
Menstrual History: 
Family history: 
CLINICAL EXAMINATION 
Extraoral Examination: 
 
Facial asymmetry 
Temporomandibular joint 
 
  
Intraoral examination: 
Mouth opening (interincisal distance): 
Size and Shape of mouth: 
Jaw movements: 
 
 Teeth:  
 
 Gingiva: 
 
 Alveolar mucosa: 
 
 Labial and buccal mucosa: 
 
 
 Hard palate: 
 
 
 Soft Palate: 
 
 
 Pillar of fauces and Tonsils: 
 
 
 Tongue: 
 
 
  
 Floor of the mouth: 
 
 
 Retromolartrigone: 
 
Provisional diagnosis: 
 
 
 
Investigations: 
 
1) Laboratory investigations: 
 
A) Blood: 
RBC Count: 
Total WBC count:  
Differential count:  P     L     E                                      Bleeding time: 
Haemoglobin %:                                                           Clotting time: 
Peripheral smear: 
Erythrocyte sedimentation rate: 
 
B) Urine: 
Glucose: 
 
Clinical diagnosis: 
 
Treatment plan: 
 
 
  
                                                           ASSESMENT FORM 
Name:                             Age/Sex:                           Op.No:           Serial No: 
Diagnosis:                                                                     Grade: 
 
CLINICAL PARAMETER 
1. Pain or Burning Sensation (VISUAL ANALOG SCALE): 
 
2. Mouth Opening: (Interinicisal Distance) 
BEFORE TREATMENT AFTER TREATMENT 
              ………mm                          ………mm 
 
HOMOCYSTEINE EVALUATION 
BEFORE TREATMENT AFTER TREATMENT 
              ………µmol/L                          ……… µmol/L 
 
  
TRIPARTITE AGREEMENT 
This agreement herein after the “Agreement” is entered into on this day ------------
-----between the Tamil Nadu Government Dental College and Hospital represented by its 
Principal having address at Tamil Nadu Government Dental College and Hospital, 
Chennai – 600 003, (hereafter referred to as, ‘the college’) 
And 
Prof Dr. G.V. MURALI GOPIKA MANOHARAN MDS., aged 50 years working as 
Professor in Department of Oral Medicine and Radiology at the Tamil Nadu Government 
Dental College, having residence address at Old No:3,New No:5,Avvaiyar Street, 
Nilamangai Nagar, Adambakkam,Chennai -600088 (Herein after referred to as ‘Principal 
Investigator’) 
And Dr. M.GAYATHRI aged 29 years currently studying as Post Graduate student in 
Department of Oral Medicine and Radiology, Tamil Nadu Government Dental College, 
residing at Valara, Natukkal (PO), Chittur (TK), Palakkad (DT), Kerala. Pincode- 
678554. (herein after referred to as the ‘PG and co- Investigator’). 
Whereas the PG student as part of her curriculum undertakes this research on 
“Evaluation of Serum Homocysteine as Prognostic Marker of Oral Submucous 
Fibrosis” for which purpose the Guide shall act as Principal investigator and the college 
shall provide the requisite infrastructure based on availability and also provide facility to 
the PG student as to the extent possible as a Co- investigator.  
Whereas the parties, by this agreement have mutually agreed to the various issues 
including in particular the copyright and confidentiality issues that arise in this regard. 
Now this agreement witnessed as follows 
1. The parties agree that all the Research material and ownership therein shall 
become the vested right of the college, including in particular all the copyright 
in the literature including the study, research and all other related papers. 
2. To the extent that the college has the legal right to do go, shall grant to licence 
or assign the copyright so vested with it for medical and/or commercial usage 
of interested persons/ entities subject to a reasonable terms/ conditions 
including royalty as deemed by the college. 
3. The royalty so received by the college shall be shared equally by all the three 
parties. 
4. The Co-investigator and Principal Investigator shall under no circumstances 
deal with the copyright, Confidential information and know – how – generated 
during the course of research/study in any manner whatsoever, while shall sole 
west with the college. 
  
5. The Co-investigator and Principal Investigator undertake not to divulge (or) 
cause to be divulged any of the Confidential information or, know – how to 
anyone in any manner whatsoever and for any purpose without the express 
written consent of the college. 
6. All expenses pertaining to the research shall be decided upon by the Principal 
investigator/ Co-investigator or borne sole by the PG student (Co-investigator) 
7. The college shall provide all infrastructure and access facilities within and in 
other institutes to the extent possible. This includes patient interactions, 
introductory letters, recommendation letters and such other acts requires in 
this regard. 
8. The Principal Investigator shall suitably Guide Co-investigator the Student 
Right from selection of the Research Topic and Area till its completion. 
However the selection and conduct of research, topic and area of research by 
the student researcher under guidance from the Co-Investigator shall be 
subject to the prior approval, recommendations and comments of the Ethical 
Committee of the College constituted for the purpose. 
9. It is agreed that as regards other aspects not covered under this agreement, but 
which pertain to the research undertaken by the Co-investigator, under the 
guidance from the Principal Investigator, the decision of the college may be 
binding and final. 
10. If any dispute arises as to the matters related or connected to this agreement 
herein, it shall be referred to arbitration in accordance with the provisions of 
the Arbitration and Conciliation Act, 1996. 
                In witness whereof the parties hereinabove mentioned have on this day month 
and year herein above mentioned set their hands to this agreement in the presence of the 
following two witnesses. 
 
 
College represented by its Principal                                         PG Student 
 
 
Witnesses                                                           Student Guide   
 1. 
           2. 
 
